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Although the pharmaceutical sector in Armenia is currently mainly established, some 
challenges still cause a big concern. Such facts as a lack of important policies on 
pharmaceuticals, an outdated legislation and a lack of regulation suggest that the 
pharmaceutical policy process in Armenia is not effective enough and its insufficient 
effectiveness is one of the most important barriers for successful implementation of 
pharmaceutical reforms in the country. The goal of this capstone was to analyze 
pharmaceutical policy process in Armenia and other Newly Independent States and to 
develop recommendations for Armenia. Data and information were obtained from 
publication searches and unpublished sources; two interviews with key informants were 
conducted – one from Armenia and one from Russia.  
It was defined that the main challenges in in the Armenian pharmaceutical sector are a 
lack of access to medicines, appearing of counterfeit products and irrational use. The results 
of assessment of the current pharmaceutical policy framework in Armenia have shown that 
17 of 44 policies recommended by the World Health Organization (WHO) are approved and 
additional 11 are implemented although are not formally approved. The results of the 
assessment also shown that the number of policies introduced in the different components 
varies: the best ratio of approved to recommended policies is observed in the area of 
Regulation and Quality Assurance while the no policies have been developed on 
Monitoring; only a few policies are available in the fields of Affordability and Rational Use. 
Assessment of effectiveness of Pharmaceutical policy process (PPP) in Armenia conducted 
according to process and outcome indicators developed has shown that PPP in Armenia is 
not sufficiently effective because process often do not reach its outcomes – well developed 
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and actively discussed drafts of policy documents are not approved without any clear 
reason, plans for implementation of those that were approved are conducted only partly and 
evaluation is never done. Strengths and weaknesses of PPP in Armenia were defined based 
on analyzing the situation in the country. 
  Based on studying experience of Newly Independent States (NIS) on PPP some 
lessons that can be used by policy-makers in Armenia were formulated: having formally 
approved document of NMP can be considered to be useful for improving the situation in 
the pharmaceutical sector; it is preferable to approve a NMP document at the governmental 
or higher level; it is important to make a draft of NMP document publicly available and 
provide conditions for wide consideration with involving different stakeholders; it is also 
important not only collect suggestions, but also to take them into account; due to absence of 
system of monitoring and evaluation countries are not able to evaluate their progress in the 
pharmaceutical sector even if they fix changes of some indicators; patients’ including 
consumers’ organizations are currently not able to make a difference in the pharmaceutical 
policy process in NIS. Framework of pharmaceutical policy process involving advocacy 
coalition was developed. 
Recommendations for different stakeholders were developed. For the Government: 
to create a Multi-sectoral Commission responsible for pharmaceutical policy issues; to 
ensure that the Commission consists of representatives of different stakeholders including 
organizations representing patients’ rights; to ensure an access of media to meetings; to 
ensure transparency of the commission’s activity; to create and introduce mechanisms for 
enforcement of existing legislation in the pharmaceutical sector. For the Ministry of Health: 
to implement comprehensive assessment of the pharmaceutical sector; to create a working 
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group consisting of leading national experts and representatives of different stakeholders to 
develop a draft of a National Medicines Policy document; to develop a draft of the five-year 
Implementation plan together with NMP and present it together with a policy document 
draft; to consider drafts with all the interested stakeholders during initially decided period of 
time, make changes based on presented comments and approve it as a Government 
Resolution; to create in MoH a special unit responsible for monitoring and evaluation of 
NMP; to create a Public Commission (involving representatives of patients’, consumers’ 
and other non-governmental organizations) to be involved in considerations of the results of 
policy monitoring and evaluation; to provide transparency of unit’s activity and results 
received; to monitor PPP according to indicators suggested and to provide the results to 
above- mentioned Public Commission for consideration and revision; to calculate, identify 
and ensure funding needed for policy implementation. For Public (Non-Governmental) 
organizations - both professional associations and representing patients’ interests: to 
participate actively in pharmaceutical policy formulation and consideration; to be informed 
about the results of monitoring and evaluation and possible changes in policy; to create a 
strong advocacy coalition involving professional associations and consumer’s rights 
organizations, media and so forth, that would be able to defend interests of patients. For 
International Non-Governmental) organizations: to provide some funding to ensure active 





Armenia is one of twelve (of the total fifteen) former Republics of the Soviet Union 
which were and are still referred to as the Newly Independent States (NIS). In 1991, 
Armenia formally declared its independence and started the transition process from socialist 
to market-oriented economy. In its attempts to reach quick achievements Armenia selected a 
strategy of rapid reforms in economic and other sectors. Similar to other NIS, Armenia has 
faced numerous political, economic and social challenges. “Transition has had a serious and 
long-term impact on the income and well-being of the population.” (Hakobyan, 2006, p.xv).  
Today the socioeconomic situation in the country is much improved, including the area 
of health care. However, many challenges still exist because  implementation of unique 
comprehensive reforms (cardinally changing the legislation, an organization structure,  
supply system,   financing, pricing and payment systems, etc.) under the conditions of 
additional difficulties of the transitional period (such as the collapse of the former supply 
systems,  lack of funding, lack of experience, some wrong assumptions, psychological 
transformation, etc.) was an extremely difficult task and the twenty years period of time was 
not sufficient to overcome completely problems appeared due to transition to another 
economic system and the collapse of the country (the former USSR).  For example, although 
the pharmaceutical sector in Armenia is currently mainly established, a lack of access to 
medicines, appearing of counterfeit products and irrational use still cause a big concern.  
At the same time it seems that although objective difficulties (lack of funding, lack of 
resources, etc.) including those caused by the transition time have been and continue to be a 
significant barrier for improvement of the situation, outcomes in the pharmaceutical sector 
could be better if the Government and other main stakeholders would make more efforts in 
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this field and if these efforts would be better managed. Recently the President of Armenia S. 
Sargsyan has criticized the situation in the health care including issues related to 
pharmaceuticals as well as inaction of officials in the Ministry of Health and other 
organizations (Regnum, 2012).  This clearly indicated a lack of efforts at the Governmental 
level that can be a serious constraint for successful pharmaceutical policy. Furthermore, 
such facts as a lack of important policies on pharmaceuticals, an outdated legislation and a 
lack of regulation suggest that the pharmaceutical policy process in Armenia is not effective 
enough and its insufficient effectiveness is one of the most important barriers for successful 
implementation of pharmaceutical reforms in the country.  
There are currently some political signs in Armenia (attention from the President to 
problems related to medicines and his promises about improvements in this field expressed 
during election campaign; increased support on the part of the Public to representatives of 
policy opposition that forces the Government to pay more attention to social problems 
including health care) and opportunities (relatively new Minister of Health who is interested 
in improving performance in the pharmaceutical sector and is able to provide necessary 
political will, recently approved Governmental decision on the program addressing 
problems in the pharmaceutical policy) which are able to bring issues related to medicines to 
policy agenda and create conditions for reform implementation. Nevertheless, it is hard to 
expect that a comprehensive pharmaceutical reform will be implemented successfully until 




National pharmaceutical policy as a framework to address challenges in the 
pharmaceutical sector 
According to the World Health Organization (WHO) recommendations, a national 
medicines policy (NMP) provides a common framework within which various problems 
related to pharmaceuticals, especially those which are complicated and interdependent, can 
be addressed (WHO, 2001). NMP presents the medium- to long-term goals and strategies 
aimed at achieving them for the pharmaceutical sector which are set by the government; it 
“is a commitment to a goal and a guide for action” (WHO, 2003, p.1). When suggesting 
having a comprehensive pharmaceutical policy, WHO recommends countries have a 
formally approved NMP document covering the following components: selection of 
essential medicines, affordability, financing options, supply systems, regulation and quality 
assurance, rational use, research, human resources, monitoring and evaluation (WHO, 2001; 
WHO, 2003).  “WHO recommends that all countries formulate and implement a 
comprehensive national drug policy (NDP)” (WHO, 2001, p.4). According to the WHO 
data, in 2007 62 (of 118 covered) countries had an official NMP (WHO, 2009). Currently 
mainly low- and middle- income countries develop such a comprehensive policy. Australia 
was one of the first developed countries that approved an official comprehensive NMP in 
2000 (WHO, 2003). In 2011 “Medicines policy 2020” was approved in Finland (MSAH, 
2011). Comprehensive NMP seems to be especially important for countries carrying out 
large-scale reforms, and all the Newly Independent States are such countries.  
The approaches to a nation’s pharmaceutical policy used by Roberts & Reich (2011) and 
Seiter (2010) are slightly different from those of WHO; in particular, when considering 
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pharmaceutical policy these authors do not focus on a comprehensive National policy 
document. Roberts & Reich (2011) mean by pharmaceutical policy “conscious efforts of 
national governments to influence the functioning of these subsystems”; these subsystems 
are the following: R&D, clinical trials, registration, manufacturing and packaging, 
procurement and importing, supply chain, dispensing and sales, use (p. 5). Seiter (2010) 
defined policy as “conscious attempt of public officials or executives entrusted with public 
funds to achieve certain objectives through a set of laws, rules, procedures, and incentives” 
(p.1). 
For this Capstone I define the pharmaceutical policy as the results of conscious attempts 
of national legislators, the Government and other public officials to influence the 
functioning of the pharmaceutical sector through a set of or separate law(s), regulation 
document(s), orders and/or actions including approval and implementation a comprehensive 
National medicines policy document. 
Based on key attributes of public policy suggested by Birkland (2010), I would suggest 
the following attributes of the pharmaceutical policy: 
 Pharmaceutical policy is made by public official even if ideas/suggestions/drafts 
of documents come from outside or are developed through collective efforts with 
other stakeholders. 
 Pharmaceutical policy is intended to be implemented not only by public officials, 
but also by different public and private institutions having their own interests. 
 Pharmaceutical policy is mainly made in response to the problem(s) related to 
medicines. 
 Pharmaceutical policy is both - what the government choses to do and not to do.  
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Approaches to Pharmaceutical Policy Process 
According to Birkland (2011), the term “policy process” suggests existence of a system 
“that translates policy ideas into actual policies that are implemented and have positive 
effect” (p.25).  My experience with evaluating the pharmaceutical policy process suggests 
that policy ideas are not always are implemented even if policy is approved, and the effect 
of policies is not always positive even if positive outcomes have been planned. Roberts & 
Reich (2011) suggest three types of possible government failures related to the 
pharmaceutical sector: goals/priorities failure (wrong goals/priorities are chosen), policy 
design failure, and implementation failure; these three types have been defined based on the 
proposition to divide the governments’ actions into tree main stages and then evaluate 
whether appropriate actions are made at each stage. Because lack of action is also a policy, I 
would add to these three failures also failure to identify and define problems requiring 
attention due to what nothing will be done to solve them. 
Thus, I would define policy process for this capstone as all the actions (made or not 
made/although were necessary by legislators and public officials from governmental 
institutions) intended to identify/define problems and approve, implement and evaluate 
pharmaceutical policy(s). It can be a system if actions are defined in some way and 
relatively sustainable such as a pharmaceutical policy process suggested by WHO for NMP 
or if it is a regulatory process used for approval of legislative documents through which a 
country introduces its policies. However, if the efforts are chaotic and sporadic and lead to 
nowhere, the way they are made cannot be defined as a system, although I would consider 
them as a policy process because they include some stages of it, for example 
developing/considering a policy proposal.  
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According to WHO’s recommendations (WHO, 2001), NMP process includes three 
main stages: formulation/development, implementation and monitoring. The development 
process leads to formulation of NMP document; implementation means realization of 
strategies and measures intended for achieving objectives/tasks on the basis of the plans 
developed; monitoring and an evaluation allow to identify progress towards meeting 
goals/objectives and, if necessary, to bring in appropriate correctives. 
 Roberts & Reich (2011) describe the pharmaceutical reform cycle as consisting of 6 
steps: identifying problem, diagnosing the causes, developing a plan, getting political 
approval, implementing, monitoring and evaluating. They suggest 5 “control knobs” as a 
guide for the process of policy developing (financing, payment, organization, regulation, 
persuasion). In his book Seiter (2010) tries to avoid any of the above mentioned two 
frameworks; he replicates an order in which the World Bank diagnoses and addresses issues 
- he uses stakeholder analysis to identify the actors and understand their motives and a 
“pattern recognition” approach - to understand complex problems in the pharmaceutical 
sector. 
Why worry about Pharmaceutical policy process? 
Understanding importance of the pharmaceutical policy process (PPP) is an 
important lesson learned by the countries during a National Medicines Policy formulation 
and implementation. It is difficult to expect good policy outcomes if process of policy 
formulating, implementing and monitoring is not appropriately organized and managed.  It 
is also important to remember that there are certain factors (stakeholders’ interests, political 
dynamics, the current situation in the pharmaceutical sector and other local conditions, etc.)  
influencing PPP and being able to cause policy success or failure; so they should be taken 
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into account and carefully addressed through appropriate strategies during policy process. It 
is difficult to expect real progress in the pharmaceutical sector without ensuring that such 
important activities as consultations and discussions, involving all interested parties, 
collecting evidences, planning implementation, and others were incorporated in PPP. WHO 
in particular stresses that a medicines policy “without an implementation plan remains a 
dead document” (WHO, 2001, p.11).  
According to MSH (2011), although PPP should be manageable yet few countries 
have implemented all aspects of their policies successfully because of existing constraints. 
The following factors are considered to be the main constraints: lack of political will, lack of 
resources, opposition, and corruption; and the following are expected to be facilitating 
factors: support of domestic and international interest groups, technical expertise, the 
presence of committed people in the MoH, shared values (MSH, 2011).    
Due to insufficient attention to PPP some countries have not been able to reach the 
objectives established successfully, despite the fact that a NMP document has been 
formulated and authorized. For example, the generics labelling and advertisement policy in 
Thailand failed because of the resistance of the pharmaceutical industry; policy was aborted 
despite a ministerial order for its promulgation (the Juridical Council ruled that the Order 
was unconstitutional (Phanouvong et al. 2002). This example illustrates the importance of 
involving all the main stakeholders, in this case - the pharmaceutical industry, in a process 
of policy formulating. WHO suggests that “The policy process is just as important as the 
policy document” (WHO, 2001, p.5).  The analysis of the situation in Yemen where the 
policy on creating an effective public pharmaceutical supply system failed in 2005 showed 
that the revolving fund proposal has not been adequately implemented through a detailed 
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implementation plan, the government had shown insufficient commitment to funding, 
corruption took place and expected patients’ contributions were not realistic (MSH, 2011). 
This example illustrates the importance of planning, government’s commitment, and 
developing evidence-based policy that takes into account the results of local situation 
assessment.  
There are also known examples of success in implementing NMP when appropriate 
strategies are used for providing good PPP. For example, the success of the implementation 
NMP introduced in Lao P.D.R. is considered to be due in part of emphasis on operational 
research; it was built in the pilot program in order to bridge gap between policy and practice 
and to provide evidence for further policy making. Building the research component in 
NMP made possible to monitor and evaluate implementation of pilot in five districts and 
compare the results with control districts, to find out continuing problems and to use the 
results of the research when revising NMP in 2001(MSH,  2011). Another well-known 
example is collaborative approach used by Australia (Phanouvong et al. 2002, MSH, 2011). 
In 1991 the Minister formed two advisory groups to involve all the interested parties to 
contribute positively to the development and implementation of policy. After several years 
of work in late 1999 a policy document taking into account elements of social and economic 
policy was launched; it has four objectives based on active partnership. The policy also 
recognizes a role of consumers and all partners have committed to consult with consumer 
representatives. In 2010 the policy was still active (MSH, 2011). Consumers and other 
partners continue to work together; in 2009 the first NMP Partnerships Forum was 
organized to identify key areas where there is need for improvement and then they are 
organized every year (Walsh, 2011). According to Walsh, a member of the Australian 
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National Medicines Policy Committee providing consumer expertise, “The policy can only 
achieve its objectives and result in real benefits for consumers through partnership and 
collaboration” (Walsh, 2011, p.2). 
Based on the results of a special study entitled Medicines for All? The challenge for 
developing and implementing national medicinal drug policies in Australia, Thailand, the 
Philippines and Laos and implemented in Australia in late 90s authors suggested 
considering five essential elements for effective policy implementation. They found out that 
although successful implementation of NMP depends on many important prerequisites 
“such as adequate funding, effective organizational structures, committed and qualified 
human resources, and the recognition of the plurality of opinions” certain elements were 
notable in experience of all countries studied. These elements were: “setting realizable goals 
and objectives; political will and commitment on the part of governments; legislative and 
regulatory frameworks; legitimacy; and the cooperation (and if necessary co-option) of 
stakeholders” (Phanouvong et al. 2002, p.26). 
According to authors, political will is one of the most important elements. They believe that 
commitment should be provided not only on the part of the government, including the health 
minister, the prime minister and the cabinet, but also by the main stakeholders because 
success of policy depends on willingness and capability of the key players at all levels 
including ministerial and parliamentary levels. Authors suggest reformers develop some 
skill in mobilizing and convincing main government officials and political figures. Some 
informants suggested that government officials should all be actively involved in the NMP 
formulation process. 





Thoroughly developed NMP process in Philippines  
Six special strategies intended to overcome main problems and create consensus among partners were used in 
Philippines at the stage of NMP formulating.  
1. Active use of consultations and participation. The Government took on the leading role in formulating 
NMP. During the first year of developing policy two national meeting were organized; twenty five 
documents were presented; ninety nine persons from sixty one organizations were involved. This strategy 
created a sense of collective “ownership” of the planning reforms among all involved and increased their 
readiness to defend policy.  
2. Institutionalization of policy through law and regulation. The law on generics of 1988 was the most 
important one; it was approved in 18 months after NMP approval, included guidelines on main aspects 
(generics, supply, formulary, etc.) and created a rear basis for NMP providing long term sustainability for 
it.  
3. Formulating possibly comprehensive and practical policy.  The working group used experience of other 
countries and developed comprehensive policy covering 4 main components with the objective to provide 
access to essential medicines.  
4. Involvement of the most qualified persons. It was planned that the policy is promoted by high level 
officials included minister, several deputy-ministers, members of the working group which were selected 
based on their high competence. 
5. Collection of adequate and evidence based data. Data collected by the working group provided support in 
debates on NMP.  
6. Mobilization and use if international support. The support from WHO and some countries (Japan, 
Australia) was important when policy was attacked within and outside the country.  
Thoroughly developed and comprehensive process of policy formulating was necessary because policy 
was intended to reform the pharmaceutical sector in whole. 




Authors who has slightly different from WHO’s approach to pharmaceutical policy also 
emphasize importance of pharmaceutical policy process. When considering pharmaceutical 
reforms intended to improve performance and equity, Roberts and Reich (2011) underline 
that they “strongly believe that process influences both product and politics” (p.86). 
Although the value of PPP is widely recognized and underlined in publications including 
WHO and MSH guidelines (WHO, 2001; WHO, 2003, MSH, 2011), sufficient attention is 
not always given to it. Lack of attention and, correspondingly, poor management of PPP can 
be the result of very different factors, including insufficient understanding, lack of 
knowledge, experience or motivation of the main participants, political dynamics. Good PPP 
would assist not only in reaching better outcomes, providing a quicker solution of existing 
problems, but also in ensuring the best use of resources. 
Effectiveness of Pharmaceutical policy process 
Based on the experience of countries described in the above-mentioned examples we 
can suppose that success of the pharmaceutical policy depends on effectiveness of the 
pharmaceutical policy process. In this capstone effectiveness means ability to reach 
appropriate outcomes, in particular, for the pharmaceutical policy process it will mean that 
policy(s) have been approved and implemented (law, regulation, programs, initiatives, 
orders, etc.). It should not be confused with effectiveness of the pharmaceutical policy that 
will mean that the policy objectives have been achieved (such as improved access to 
medicines or their more rational use). To monitor progress of the pharmaceutical policy and 
process towards to objectives different indicators/measures can be used. WHO has 
developed different sets of indicators. The latest set - a core indicator package (three 
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different levels) is intended for monitoring and evaluating country pharmaceutical 
situations. It includes few indicators measuring the situation with NMP (WHO, 2007): 
1.1. Is there a National Medicines Policy (NMP) document? 
a) If yes, is it an official or draft document? 
b) What year was it last updated? 
1.2. Is there an NMP implementation plan that sets activities, responsibilities, budget 
and timeline? 
a) If yes, when was it last updated?  
1.3. Is the NMP integrated into or included in the published/official national health 
policy/plan? 
a) If yes, when was the national health policy/plan last updated? 
1.4. Has a national assessment/indicator study been conducted? 
a) If yes, which topics have been studied and when was the most recent study covering 
each topic conducted: 
Overall pharmaceutical situation:  
Rational use/prescription audit: 
Access (i.e. prices, affordability and/or availability) to medicines: 
1.5. Is there a code of conduct that applies to public officials and staff involved in 
pharmaceutical related activities or posts, such as persons working in pharmaceutical 
services, medicines regulation, procurement and supply of medicines and other 
pharmaceutical divisions of the health ministry? 
There is also a special set of indicators developed by WHO for monitoring NMP 
(Brudon, 1994) which was published in 1994, however they are mainly intended to monitor 
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outputs and outcomes of policy implementation, not outputs and outcomes of policy process 
itself.  
However, WHO and MSH suggest certain recommendations related to the 
pharmaceutical policy process which have been developed based on countries’ experience. 
Based on these suggestions as well as my own experience I have developed the following 
process and outcome indicators for the pharmaceutical policy process intended to define 
whether PPP is effective and identify its strengths and weaknesses. Those process indicators 
should not be confused with process indicators suggested by WHO for monitoring policy 
during the process of implementation.  
Process indicators 
Stage of formulation: 
 Responsibilities and time-frame for policy formulation are defined (the period for 
preparing a draft should not exceed 6 months and overall time by the final 
consideration should not exceed a year). 
 Operational research is implemented to provide baseline data (not always applicable 
for legislation/regulation documents). 
 A policy paper on the issue considered is presented (should include brief description 
of the current situation, evidence based policy options and be developed by experts). 
 Stakeholder analysis is implemented. 
 Draft of a final document is presented (if it is a policy document it should include 
goals and strategies to achieve these goals; if it is legislation/regulation document, it 
should include appropriate provisions). 
 Legal basis for policy enforcement is ensured. 
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 Draft is made publicly available. 
 A national conference/meeting is organized to present the final draft (all stakeholders 
including patient/consumer organizations as well as media are invited). 
 Strategies for political support are developed and implemented. 
Stage of Implementation and Monitoring 
 Draft of Implementation plan (can be called differently) is presented. 
 Draft of evaluation program is presented. 
 Drafts are circulated for consideration. 
 Funding is provided. 
 Mechanisms providing transparency and accountability are introduced. 
 Draft of Implementation plan is formally approved. 
 Draft of evaluation program is formally approved 
Outcome indicators 
Stage of Formulation 
 Policy (policy or legislation/regulation document or program) is formally 
approved. 
Stage of Implementation and Monitoring 
 All activities in the Implementation plan are implemented. 
 The final evaluation document is presented and distributed. 
Why worry about Pharmaceutical policy process in Armenia? 
Despite the fact that the WHO suggested developing a comprehensive NMP as a written 
document and Armenian experts and policy-makers were mainly agree with this approach, 
there is still no officially approved NMP in Armenia. Although several drafts of a 
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comprehensive NMP document have been developed in Armenia since 1992 and considered 
at different high levels (Ministry of Health, Ministry of Economy on behalf of the 
Government), none have been formally approved. There is also no strategic plan on 
improvement of the pharmaceutical sector in Armenia. Since 1992 some reforms have been 
implemented, mainly in the early 90s. However some of them, for example privatization of 
pharmacies, were not well prepared.  Privatization and licensing of pharmacies were 
implemented due to changes in the country’s economic system (transition to a market-
oriented economy) in whole; however, necessary regulation to allow the pharmaceutical 
sector to perform well under the conditions of the market-oriented system are still not in 
place. Reforms related specifically to pharmaceuticals have been sporadic. The creation of 
the Scientific Center of Drug and Medical Technologies Expertise (SCDMTE) in 1992 was 
the most important of these reforms. SCDMTE was organized to carry out functions similar 
to those of the Food Drug Administration in the U.S. (only on medicines, but not on food), 
and several other functions. Because SCDMTE has a very well qualified staff of 
professionals and access to resources (registration fees), the best improvements in Armenian 
pharmaceutical sector were achieved in the area of drug authorization and related fields. 
Several important strategies were initiated by the Ministry of Health; however, their 
outcome is not really known due to absence of a system of monitoring and evaluation. The 
current legislation is already obsolete and a draft of a new law has been under consideration 
for 7 years. Regulation is still incomplete and there are no clear policies on pricing, 
distribution, rational use of medicine and other important aspects related to medicines. 
Although SCDMTE has developed a set of regulatory documents, they cannot be considered 
until a new law is approved. A Value added tax (20%) was introduced on medicines (in this 
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case it was quite rapid decision) despite serious opposition. It has led to price increases. The 
special social fund that was expected to be created based on the additional money flow 
coming with the new tax has never been established. The fact that stakeholders have not 
been involved in policy development and that there is no system to monitor implementation 
of policy decisions have been major factors explaining policy failure.  
Why compare the pharmaceutical policy process in the Newly Independent States? 
The systems of medicines supply have changed significantly since 1992 in the NIS. 
Although countries are now quite different in their size, social and economic level and other 
characteristics, at the beginning of reforms in early 90s they had a very similar situation in 
the pharmaceutical sector due to a common legislation and regulation, a common supply 
system, the same education curriculum and so forth.  After the collapse of the former Soviet 
Union in 1991, the Independent States started reforms which were necessary to transform 
the pharmaceutical system in a way it will be able to operate under the conditions of market-
oriented economy. The speed and a content of reforms differed. These variances definitely 
have led to differences in outcomes which have become more significant with the time 
passing. At the beginning of 2000s differences between countries were observed with regard 
to the structure of the sector, pricing and reimbursement systems, etc. (Drugs and Money, 
2003, p.134). Now variations have become even more significant due largely to the different 
socio-economic conditions achieved by countries. It can be said that the pharmaceutical 
sectors of these countries are currently mainly established; however such challenges as a 
lack of access to medicines, inappropriate use and some issues related to safety of medicines 
still cause a concern in all the countries of the region. Countries continue their efforts to 
improve medicines supply system and achieve the main objectives of the pharmaceutical 
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sector - providing the population of the countries with effective and safe medicines of 
appropriate quality and their rational use. Appropriately formulated and approved National 
pharmaceutical policy can make these efforts effective and improve outcomes. “In all CCEE 
and NIS countries, continuing improvements in sector management should strengthen 
recently established structures and create sustainability. National drug policies will continue 
to play a stimulating strategic role.” (Drugs and Money, 2003, p.134). 
There are only a small number of publications on the pharmaceutical policy process 
from which lessons can be learned. There are certain recommendations developed by WHO 
based on the countries’ experience that can be considered relevant to Armenia. There are 
certain important recommendations related to PPP for improving policy implementation in 
two very relevant recent publications of leading experts in this field - Roberts and Reich 
(2011) and Seiter (2010). Their approaches differ slightly from those suggested by WHO. 
Studying the experience on PPP of other Newly Independent States which went through a 
transition process similar to the process that Armenia went through, seems to be very useful.  
Goals and Objectives of this Capstone 
The goal of this capstone was to analyze pharmaceutical policy process in Armenia and 
other Newly Independent States and to develop recommendations for Armenia Research 
questions: 
 What are the main challenges related to pharmaceuticals in Armenia? 
 What is the current pharmaceutical policy framework in Armenia? 
 What are strengths and weaknesses of pharmaceutical policy process in Armenia? 
 What are the similarities and differences in the pharmaceutical policy process in the 




 What changes in pharmaceutical policy process in Armenia could make it more 
effective? 
The objectives are: 
 To review literature available on pharmaceutical policy process 
 To examine key elements of pharmaceutical policy process in twelve NIS countries: 
existence of approved NMP document, participation of main stakeholders in its 
development, existence of implementation plan and system for monitoring of NMP 
 To develop recommendations for improving the pharmaceutical policy process in 
Armenia 
Methods 
Data and information were obtained from academic searches, Google search, search of 
web sites of the World Health Organization, its Office for Europe, the Observatory (HiT 
series), and various published and unpublished sources in NIS. Two interviews with key 
informants were conducted – one from Armenia and one from Russia.  
Part I. Pharmaceutical policy in Armenia 
1. The main challenges in the Armenian pharmaceutical sector 
Lack of access to medicines. Although total pharmaceutical expenditures increased 
significantly during the last 20 years, they are still quite low when compared with other 
countries. According to the Armenia Pharmaceutical Country Profile (2010), in 2008 the 
total pharmaceutical expenditure per capita was AMD 7,030 (US$ 23). The total 
pharmaceutical expenditure includes public spending (mainly provided from the State 
Budget) and private spending (mainly out-of-pocket payments of patients). The rough 
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estimates based on the results of analysis of data received from the annual Integrated Living 
Conditions Survey of Households (ILCS) suggest that the total out-of-pocket expenditures 
on medicines per capita per year consisted of about 21 USD in 2008 and 2009, and then 
sharply increased totaling 37 USD in 2010. The share of spending on medicines also 
increased in 2010 and totaled 4% of the total expenditures of surveyed households (3.3% in 
2009 and 1.8% in 2008). This sharp increase in pharmaceutical spending is not supported by 
the data on imports for 2008, 2009 and 2010 that vary with the biggest value in 2008 
(Foreign trade, 2009, 2010, 2011) and can be only partly explained by price increases.  
 Expenditures on pharmaceuticals per household member depend on family income. 
In 2010, out-of-pocket expenditures on medicines per member of non-poor households 
(49USD per capita per year) were 3 times higher than those of the poor (16USD per capita 
per year) and around 8 times higher than of those extremely poor households (6USD per 
capita per year). This clearly shows that individuals from families with low income have 
very limited access to medicines. Although there is a pharmacy reimbursement system in 
place that covers certain social groups and patients with certain diseases (children under 7, 
disabled persons, etc.), the list of social groups does not include individuals from families 
living in poverty.  
Public pharmaceutical expenditures are also very low in Armenia. According to the 
Report on implementation of the State Budget of the Republic of Armenia for 2011, the total 
public pharmaceutical expenditures of 4.1 billion Armenian drams is about $11 million or 
3.4USD per capita per year.  Two recent studies have shown that this is not enough to cover 
needs of even a restricted population eligible for receiving medicines free of charge or with 
discounts. The study by the Economic Development and Research Center (EDRC) has 
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shown that more than 40 percent of sick people mentioned that they received only 10 
percent of medicines needed for treatment. Only 45 percent of households who have 
members from any social group or disease eligible to receive drugs with privileges, 
exercised their rights (EDRC, 2011). According to the data of the Drug Utilization Research 
Group (DURG) that implemented study among households in all the regions of Armenia in 
2011, patients with certain diseases eligible to receive pharmaceuticals free of charge got 
only 23% of the free medicines they used during the last 2 weeks, in particular less than 
25% of medicines for children under the age of 7 were provided for free (Melikyan, 2011). 
During the study in 2008 “Health officials acknowledged that allowances to polyclinics for 
adult drugs were inadequate, and many patients entitled to free outpatient drugs were forced 
to purchase them in the market.” (PHCR, 2010, p.7). 
 Because the majority of patients pay for medicines out-of-pocket, pharmaceuticals 
are not affordable for many individuals and families. The 2008 survey has shown that 
approximately one third of the surveyed households did not get a recommended service after 
they contacted the health system; in particular for medicines, 35% of those who did not get a 
recommended service said they failed to do so “because of finances” (PHCR, 2010). In 
August 2009, many households reported foregoing medications due to financial difficulties, 
in particular 21% reduced or stopped buying the medicine they required (WFP, 2010). 
“Most households did not seek health care or did not purchase prescribed medicines for lack 
of income to cover the cost” (World Food Programme, 2010, p.32).  Although private 
pharmaceutical expenditures increased in 2010, only 50 % of representatives of households 




 High prices are one of the main factors affecting the affordability of medicines and 
treatment. Very large differences in prices of originator brand products (and brand name 
generics) and the lowest-priced generics lead to different affordability of these products. For 
example, the number of days the lowest-paid government worker needs to work in order to 
be able to pay for a standard course of treatment for arthritis (diclofenac, 50 mg capsule or 
tablet) is 10.8 days if originator brand product is used and 0.78 day for the lowest-priced 
generic (Kazaryan, 2011). It should be noted that physicians often prefer to prescribe 
originator brand products or brand name generics. 
Irrational use of medications. Although there is  a lack of research on medication use in 
Armenia, inappropriate use of pharmaceuticals can be easily predicted based on the 
existence of the majority of factors known to lead to misuse of medicines, in particular, lack 
of updated treatment guidelines or their monitoring, inadequate knowledge among 
professionals and population, unrestricted distribution of Prescription Only Medicines 
(POM - medicines which can be dispensed only if prescription is available) from pharmacies 
despite an appropriate provision in the law on medicines, aggressive promotion by 
pharmaceutical companies and so forth. The results of household surveys have shown that 
68% of POM used by any of household’s members during the previous 2 weeks, including 
antibiotics, were bought without prescription (Melikyan, 2011). Another study has shown 
that only 58.5% of antimicrobial medicines sold by pharmacies in Yerevan were prescribed 
by physicians, 10.5% were advised by pharmacist/technician, 31% - by other persons; 
77.2% of prescription only antimicrobials were sold without prescription (Hakobyan, 2011). 
The essential medicines list (EML) was firstly introduced in Armenia in 1992 and was 
updated on a regular basis until 2007. However after 2007, a revised version was not 
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approved. In 2006, a new mechanism requiring physicians to prescribe medicines from 
EML to patients covered by the reimbursement system was introduced. However, physicians 
continue to prescribe pharmaceuticals out of the EML. Analysis of medicines used by 
members of households studied shows that only approximately 43% of medicines were from 
the EML (Melikyan, 2011).  
 Although clinical guidelines for the most primary health care diseases were 
developed and approved in early 2000s, the majority of them have not been updated. The 
study in 2006 showed that prescribing practices vary widely among providers. Treatment 
guidelines were not available at all facilities studied and actual prescribing practices for 
studied conditions varied significantly from treatment recommendations (Lee, 2007). 
2. Brief history of Armenian pharmaceutical reforms 
Early years 
In 1992, after the proclamation of independence, the Republic of Armenia started to 
formulate its own pharmaceutical policy. Recommendations of the WHO, as well as local 
conditions were taken into account as the basis for policy development. Armenia was faced 
with the need to implement comprehensive pharmaceutical reform covering almost all the 
components of the pharmaceutical sector. The early years were very successful. In 1992, the 
Government established the Armenian Drug and Medical Technology Inspection (then it 
was renamed and called SCDMTE, and then renamed again as the Scientific Centre of Drug 
and Medical Technology Expertise - SCDMTE), which was partly modeled on the United 
States Food and Drug Administration (FDA) (Hakobyan, 2006) taking into account the 
recommendations of WHO for small countries and local conditions. SCDMTE (then Drug 
Inspection) was the first organization with National Drug Regulatory Agency’s functions 
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created in the Newly Independent States. Before that time all medicines evaluation and 
authorization functions had been managed by a single set of institutions in Moscow. 
Armenia created a new system for medicines evaluation and registration soon after 
independence, creating the opportunity for the country to authorize medicines and control 
their quality on the pharmaceutical market. SCDMTE was also responsible for licensing and 
inspecting producers, wholesalers and pharmacies, monitoring drug adverse reactions and 
some other functions. A new laboratory was also created at SCDMTE with support of the 
Gulbenkian Foundation. The new laboratory was supplied with modern equipment and 
became the best equipped quality control laboratory at the Drug Regulatory Agencies 
created on the territory of the former USSR.  
SCDMTE proposed to the Ministry of Health that it should adopt the Essential Drugs 
concept recommended by WHO as the basis for national policy on medicines. As the result, 
in 1992 the first version of Armenian Essential Drugs List (EDL) and some corresponding 
strategies were approved by a special Decree of the Minister of Health. After long 
consideration a draft of the first law “on medicines” was approved in 1998. It was developed 
by SCDMTE in 1994 and then was discussed with some stakeholders including the Ministry 
of Health, other ministries, and the Armenian pharmaceutical association.  
The former state “Armpharmacy” Republic Association which comprised all the 
pharmacies and one warehouse in Armenia was reformed. All pharmacies were privatized 
and numerous new private pharmacies were founded and licensed which created the 
opportunity for increasing the availability of medicines.  In 1993 the Department of 
Pharmacy was established at the National Institute of Health for providing continuing 
education for Armenian pharmacists. 
 30 
 
The success in reforming the pharmaceutical sector in Armenia during the early years of 
independence was possible due to some important factors: leadership by the Head of 
SCDMTE, high level of motivation and high competence of SCDMTE’s staff (the best local 
professionals were involved); relying on evidences as much as possible (the most of the staff 
were researchers) when developing policy suggestions, political will provided by the 
Ministry of Health.  
Recent years 
The Ministry of Health has introduced system of reimbursement based on the Essential 
Medicines List (MoH, 2006) and some other initiatives. Some strategies intended to 
improve national security in the area of Health care and, in particular in the pharmaceutical 
service, were approved by the appropriate Government Decree (RA Government, 2010a).  
The USAID-funded Competitive Armenian Private Sector (CAPS) project together with 
local manufacturers initiated the development and approval of regulations on Good 
Manufacturing practice (RA Government, 2010b) and some other documents important for 
development of pharmaceutical industry in Armenia.  
In 2012 the Government formally recognized and addressed some urgent challenges in 
the pharmaceutical policy, including ineffective centralized and not centralized 
procurement, lack of state control in the Health care system, and ineffective system of 
medicines evaluation (RA Government, 2012).  
3. National medicines policy document in Armenia 
Drafts of National medicines policy document and their content 
Armenia’s first NMP document - “Concept of a program of the pharmaceutical sector 
development in the Republic of Armenia” appeared in 1993 (Kazaryan & Melikyan, 
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1998/99). It was based on the WHO recommendations and the local situation. The document 
was comprehensive and included the following sections: introduction (problems in the 
sphere of medicines supply and their reasons, the aim and tasks - long-term and mid-term 
for the first five years' period); the main principles of public policy in the pharmaceutical 
sector at the early stage (1993-1997) - separately for nine components; the brief 
characteristics of resources; the main mechanisms of NMP implementation (strategies) for 
the first stage – again separately for nine components; structure of pharmaceutical 
management (a scheme of management, units responsible for each of mechanisms);  plan of 
implementation (for 1993-1997) . The main components determined were the following: 
legislation, policy and management, pharmaceutical industry, medicines supply, rational 
use, quality assurance, research, human resources, and information. In fact, the Concept was 
a first draft of NMP for Armenia. The document was developed by the group of leading 
experts based on detailed assessment of the current situation and opportunities for 
development.  A draft was successfully approved by the Ministry of Health and then by the 
Ministry of Economy on behalf of the Government (Kazaryan & Melikyan, 1998/99). 
However, due to political changes in the Government and changes in policy development 
approaches in the country, the developed document has never become an official strategy.  
The next drug policy development was the “Document of Armenian National Drug 
Policy” that emerged in 1995. The document included the following sections: introduction; 
objectives and tasks, NMP elements and guidelines for their introduction (ADMTA 1995; 
GPHCDP 2006).  Although this document was not approved by any formal authority in 
Armenia and, correspondingly, could not be considered an official NMP document that is 
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obligatory for implementation by other organizations in the country, it became a very good 
guide for further activity of SCDMTE that started to implement strategies described there. 
In early 2000s, two different drafts of NMP were developed to become a part of 
National Health Policy document and submitted to the Ministry of Health. A draft submitted 
by NGO DURG included a brief assessment of the current situation, goals, objectives and 
strategies intended to solve main problems revealed from the assessment. Strategies were 
developed for all components suggested by WHO for NMP document.  
The last data available about the NMP document comes from the Armenia 
Pharmaceutical Country Profile (Armenia Pharmaceutical, 2010) that states “The National 
Health Policy Document is a draft. The NMP is a part of this document” (p.41). This means 
that NMP was formulated as a part of a draft of the National health policy document 
however the latest is still a draft because has not been approved yet.  The Armenia 
Pharmaceutical Country Profile also informs that the draft was updated in 2006. Because the 
Profile was submitted in 2010, it is evident that the draft has not been approved yet at that 
time and we have to assume that there were no officially approved NMP in the country in 
2010. 
Thus, despite numerous efforts, Armenia does not have a formally approved 
comprehensive National Medicines Policy document.  
Formulation of NMP document 
The process of NMP formulation began in Armenia in 1992 when the Government 
charged the ministries to design the concepts of corresponding sectors development. MoH 
started developing two documents: the concept of a program of health care development and 
the concept of a program of pharmaceutical sector development. Two working commissions 
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of experts were created. The working group on the pharmaceutical service development 
consisted of representatives of various sectors: research institutes of the Academy of 
Sciences and the MoH, the state enterprise, “Armpharmacy” at MoH, and the State Medical 
University. An economist (expert at the Standing commission on health care and social 
affairs at the Supreme Council of Armenia) was also included in the working group. The 
vice-president of SCDMTE was selected to be the Chairman of the working group. The 
group worked under supervision of the Chairman of SCDMTE; all the activities were 
implemented on voluntarily basis. A detailed analysis of the pharmaceutical sector was 
carried out, and the results were submitted as a separate detailed review. A draft of the 
document “Concept of pharmaceutical service development in RA” was developed. Works 
in progress and drafts were discussed at meetings at MoH and the meeting of the Ministry of 
Economics Board when a draft was approved on behalf of the Government. The whole 
process took about one year. 
The “Document on a National medicines policy of RA” produced in 1995 was 
formulated by SCDMTE’s staff. It was considered and approved at the joint meeting that 
took place in SCDMTE with participation of representatives of various interested parties of 
the pharmaceutical sector: MoH RA, SCDMTE, and the WHO Regional Office for Europe. 
The third time the issue of a NMP document was on the policy agenda was in 2002 – 
2003. The MoH RA initiated the development of a health policy document. It was planned 
that document would be approved by a Resolution of the RA Government and become a 
guide for the sector’s development. One of chapters of a document was planned to cover the 
issues related to supply of medicines (in fact NMP). Two independent drafts covering 
pharmaceutical policy issues were submitted to the MoH. One of them was presented by the 
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Armenian nongovernmental organization, “Drug Utilization Research Group” (“DURG”). A 
draft was developed on the basis of a detailed assessment of the pharmaceutical sector 
(Kazaryan 2003) and included interviews with representatives of various Ministries, in 
particular, Economics and Finance, Industries and Trade, Social Affairs, as well as 
professionals from the National Institute of Health, pharmaceutical associations, and 
consumer organizations. This draft was discussed with representatives of WHO and 
international experts from the Department of Public Health at the London School of 
Hygiene and Tropical Medicine. Another draft was developed by SCDMTE. A draft health 
policy document was discussed at several meetings organized by the MoH RA with some 
interested parties.  
Implementation and monitoring of NMP 
Because no draft was formally approved and adopted, there has been no plan 
implementation. However, SCDMTE started implementing some important strategies and 
tried to promote them through MoH.  For example, the EML has been regularly updated. 
Standards Treatment Guidelines for many diseases have been developed.  
From 31
st
 May till 1
st
 July, 2001 a special meeting took place in SCDMTE that was 
dedicated to analysing SCDMTE’s activities to implement a medicines policy since 1994 by 
the SCDMTE and MoH in a close cooperation with the Regional Office for Europe. More 
than 60 persons, including representatives of the various interested parties, attended the 
meeting. The special report was developed and distributed (ADMTA, 1995). 
4. Pharmaceutical policy framework 
According to the World Health Organization’s approach, a National Medicines Policy is 
“a comprehensive framework in which each component plays an important role in achieving 
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one or more of the general objectives of the policy” (WHO, 2001, p.6). WHO suggests the 
following main components: selection of essential medicines, affordability, financing 
options, supply systems, regulation and quality assurance, rational use, research, human 
resources, monitoring and evaluation and also provides the key policy issues for each 
component (WHO, 2001; WHO, 2003). Although there is no approved NMP document in 
Armenia, some important policies have been adopted through legislation and regulatory 
documents. There are two types of documents: legislative (laws approved by the National 
Assembly) and sub-legislative (Government Resolutions and Decrees of Ministers approved 
by the Ministry of Justice). Assessment of the current pharmaceutical policy framework in 
Armenia in this capstone is conducted by identifying whether key pharmaceutical policy 
issues recommended by the WHO are approved or, although not approved, are implemented 
in Armenia (Table 1). The set of key policies, listed in the WHO issue of the Policy 
Perspectives on Medicines series “How to develop and implement a national drug policy” 
(WHO, 2003) was used for this assessment.   
The data presented in the table 1 indicate that although many key policies are approved 
and implemented in Armenia, some of them have not been adopted. According to this 
assessment 17 of 44 policies recommended by WHO are approved and additional 11 are 
implemented although are not formally approved. It is important to increase the number of 
approved and implemented policies in order to improve medicines use. A special study was 
recently implemented to demonstrate evidence of NMP effectiveness (Holloway, 2012). 
Authors have had the objectives to determine whether medicine use is better in those 
countries with certain pharmaceutical policies compared to those without and whether 
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medicines use improves with increasing number of policies. The results have demonstrated 
that the more policies are implemented, the better the drug use. 
The results of this assessment show that policies are mainly introduced through 
legislative and sub-legislative documents (Law “On Medicines”, certain RA Government 
Resolutions and Decrees of the Minister of Health). In 2012, a program aimed to solve 
certain problems in the pharmaceutical policy was approved as a policy document by the 
Government (Government, 2012). Some policies, although not adopted, are implemented, 
mainly by the staff of SCDMTE. Currently, the results of this practice are positive because it 
allows Armenia to achieve certain important outcomes. For example the (unapproved but 
adopted) use of the effective medicines selection process and objective selection criteria 
provide the opportunity to ensure development of appropriate EDL. However, it is important 
that such practice be changed and appropriate policies be introduced to provide 
sustainability and decision-making that is independent from personal ethical and 
professional preferences of the SCDMTE staff.  
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Table 1. Status of key pharmaceutical policies in Armenia  
 
Selection of essential medicines 
 
Key policies suggested by 
WHO 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Adoption of the essential 
medicines concept to 
identify priorities for 
government involvement in 
the pharmaceutical sector 
The essential medicines concept was 
accepted from the first years of 
Independence. The first List of Essential 
Medicines (EML) in Armenia was 
authorized in 1994. It is periodically 
updated (mainly every 2 year until 2007; 
the last approved EML is of 2007 as 
developed drafts were not approved; 
currently a new draft is developed and 
three is command from MoH to speed the 
process). 
 
Law “On medicines” (Article 18) states 
that availability and affordability 
medicines from EML is ensured in the 
Republic of Armenia. 
Law “On medicines”, 
1998 (Article18) 






The last EML was 
approved by the Decree of 
the Minister of Health N 





Although the concept is accepted 
and commitment is stated in the 
Law, mechanisms necessary for 
implementing the concept, are 
mainly not developed; the only 
exception is requirement to prescribe 
medicines from EML to patients 
who receive medicines free or with 
privileges.  
 
Also, SCDMTE ensures a priority 
registration for the essential 
medicines.  
 
Selection of essential 
medicines in a two-step 
process: (1) market 
approval; (2) selection of 
essential medicines relevant 




 There is currently no formally 
approved policy on selection 
process. However, the  staff 
currently involved in the process of 
selection, try to follow these and 
other important principles for 
selecting medicines for EML 
Defining the selection 
criteria (i.e. sound and 
  There are no currently formally 






However, the staff, currently 
involved in the process of selection, 
try to follow recommendations of 
WHO for selecting medicines for 
EML; Armenian EML is mainly 
based on the WHO Model EML and  
local morbidity data 
Defining the selection 
process (i.e. appointment of 
a standing committee, etc.) 
A special committee  - Pharmacological 
Commission responsible for selection of 
medicines for EML and other related 
issues, is appointed at MoH 
RA Minister of Health 
Order N 965 of 2006 
(there is no link available) 
There is only policy on the 
Pharmacological Commission, but 
not other aspects of selection 
process 
Ensuring a selection 
mechanism for traditional 
and herbal medicines. 
  Only products that can be defined as 
a “medicine” are considered for 
including in EML. Traditional and 
herbal products can get a “medicine” 
status only if they are evaluated and 
authorized like other products. Thus, 
there is no need for a separate 
mechanism. 
 
It is not an issue for Armenia 
because modern medicines are used 




Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Government commitment to 
ensuring access through 




For all medicines: removal 
or reduction of taxes and 
tariffs on essential 
medicines; control of 




Since 2001there is a 20% VAT 
(until 2000 medicines were exempt 
from VAT) (Hakobyan, 2006). 
There is neither control of 
distribution margins nor any pricing 
policy. There are no duties on 
imported raw materials or on 
imported finished products. 
(Armenia Pharmaceutical, 2010). 
For multi-source products 
(generic medicines and 
branded generics): 
promotion of competition 
through generic policies, 
generic substitution and 
good procurement practices 
  There is no a special generic policy. 
 
Generic substitution is not regulated 
(there is no any special provision, 
but generic substitution is 
traditionally used because it was 
allowed by the soviet time 
regulation). 
There is no good procurement 
practice policy on medicines. 
For single-source products: 
price negotiations, 
competition through price 
information and therapeutic 
substitution, and TRIPS-
compliant measures such as 
compulsory licensing, “early 
workings” of patented 
medicines for generic 
manufacturers and parallel 
imports. 
Current laws contain (TRIPS) flexibilities 
and safeguards (not specified for 
medicines (Armenia Pharmaceutical, 
2010). 
Law “On inventions, 
utility models and 








There is no policy on price 
negotiation or competition through 
price information and therapeutic 
substitution. 
 








Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Commitment to measures to 
improve efficiency and 
reduce waste 
There is a general policy on efficiency of 
centralized procurement. According to 
Law “On procurement” the State agency 
on procurement organizes centralized 
procurement (mainly through tenders) of 
certain goods including medicines, those 
are determined by the MoH; Agency also 
carries out tenders for individual health 
facilities (Armenia Pharmaceutical, 2010). 
 
In 2012, a new approach to providing 
efficiency in procurement of medicines 
was approved. 
There is a policy to restrict 
reimbursement to EML (medicines in 
EML are listed under generic names). 
Law “On Procurement” of 




&enc=utf8 (in Armenian) 
 
Decision of RA 
Government meeting “On 
approval of program on 
solving problems in state 
control  in the area of 
Health care, as well as in 
pharmaceutical policy; 
and list of measures 
ensuring implementation 
of program” of October 
18
th





RA Minister of Health 
Order N 74-N of January 
27
th, 2005 “On adopting 
the order of free or 
privileged provision of 
There are still no clear requirements 
to medicines’ procurement that 
correspond to Good procurement 
practice. 
 
It is accepted now (Government, 
2012) that practice of medicines 
procurement (both centralized and 










funding for priority 
diseases, and the poor and 
disadvantaged 
Medicines for some diseases and for 
patients from certain social groups are 
provided free of charge or with privileges 
 
RA Government 
Resolution N 1717-N of 
November 23rd, 2006 “On 
adopting the list of 
diseases and social groups 
of population entitled to 
free or privileged 
purchase of medications”  
http://pharm.am/jurdo
cs_list.php?pg=3&id=2&l
angid=2 (in Armenian) 
There is no policy on funding 
medicines for poor, pregnant and not 
disadvantaged elderly 
Promotion of medicine 
reimbursement as part of 
public and private health 
insurance schemes 
  There is no public insurance, only 
voluntary private insurance (very 
small % of population); there is no 
special policy on medicines 
Use of user charges only as 
a temporary drug financing 
option 
  There are no user charges. The 
majority of medicines are bought 
out-of –pocket; those that are 
reimbursed – are provided to 
patients for free or with 50% or 30% 
discount 
Limiting the use of 
development loans within 
identified national priorities 
  There is no special policy; however, 
loans are not used for funding 
medicines 
Following national or WHO 
guidelines for medicine 
There is a policy on donations that 








Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Promoting a public-private 
mix in medicine supply and 
distribution systems 
  All pharmacies and wholesalers in 
Armenia are private. There is only 
one public warehouse responsible 
for distribution of donations 
Committing to good 
pharmaceutical procurement 
practices in the public sector 
  There are no any special provisions 
covering procurement of medicines, 
including those suggested by good 
pharmaceutical procurement practice  
Publishing price information 
on raw materials and 
finished products 
  There is no special policy requiring 
publishing prices. Some wholesalers 
publish medicines’ prices 
voluntarily.  
Ensuring medicine supply 
systems in acute 
emergencies 
  There are no special provisions. 
Carrying out inventory 
control, and taking measures 
for prevention of theft and 
waste 
  There is no special policy. However, 
being private all wholesalers and 
pharmacies take their own measures.   
Ensuring disposal of 
unwanted or expired 
medicines 
There is a special policy in place covering 
rules on disposal of medicinal products 
and pharmaceuticals.  
“Law on waste” and Order 
of the Minister of Health 
N 03-A of March 4, 2008 
“On adopting sanitary 
rules and norms N 2.1.3-3 
“Hygienic and anti-
It was a serious problem for 
Armenia as a huge amount of 
expired medicines were kept in the 
country after receiving donations 




epidemic requirements to 
the usage of medical 
wastes in RA”. 
There is no policy on collection and 
disposal unused medicines from 
patients. 
 
Regulation and quality insurance 
 
Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Government commitment to 
drug regulation, including 
the need to ensure a sound 
legal basis and adequate 
human and financial 
resources 
  There is no a special statement about 
such commitment 
Independence of the 
regulatory authority to 
ensure that there is no 
conflict of interest 
Some functions of Drug regulatory 
authority (DRA), including medicines 
evaluation, quality control and some 
others are implemented by SCDMTE – a 
special organization at MoH. It is 
independent because mainly has 
evaluation functions; it is not responsible 
for any function related to medicines 
supply. 




functions of SCDMTE. 
 
Commitment to good 
manufacturing practices, 
inspection and law 
enforcement 
Good manufacturing practice (GMP) was 
introduced in 2010 by approval of a 
Government Decree. 
 
Policy on inspection was approved by the 
RA Government meeting in October 
2012. 
 
RA Government Decree N 
1603-N of November 25
th
 






There is no detailed/specific policy 
on law enforcement in the case of 
incompliance with GMP standards  
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General statement on “Responsibility for 
the violation of drug preparation and 
manufacture order” is included in the Law 
“On medicines” 
RA Government Decree N 
734-N of May 26
th
, 2011 
on “Approval of timeline 
for introducing rules of 
GMP in RA and 








 Decision of RA 
Government meeting “On 
approval of program on 
solving problems in state 
control  in the area of 
Health care, as well as in 
pharmaceutical policy; 
and list of measures 
ensuring implementation 
of program” of October 
18
th












Regulation of traditional and 
herbal medicines 
Some aspects related to herbal medicines 
(licensing requirement for culturing and 
sale medicinal herbs) are regulated 





There is no special regulation on 
traditional medicines 
Ensuring adverse drug 
reaction monitoring systems 
There is policy on adverse drug reaction 
(ADR) monitoring system – the statement 
in Law. 





Although there is only one sentence 
in the law, a system works well. A 
national Pharmacovigilance center 
exists at SCDMTE (Hakobyan, 
2006) 
Commitment to regulation 
of information and drug 
promotion 
There is detailed policy on medicines 
information and promotion covered by 
two laws and specific regulation 
document 
RA Law “On 





RA Law “On advertising” 
http://pharm.am/jurdocs_li
st.php?pg=3&id=1&langi
d=2 (in Armenian) 
 
RA Government Decree N 
1608-N of November 2, 
2006, “On adopting the 
order of granting 
permission to advertise 
medicines, medical 
equipment and methods of 
treatment and 







d=2 (in Armenian) 
International exchange of 
information 
  There is no special policy on this 
issue for medicines; however 
Armenia provides information to 





Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Mandated multidisciplinary 
national body to coordinate 
medicine use policies 
  There is no such policy in place.  
Development of clinical 
guidelines as the basis for 
the selection of essential 
medicines and training of 
health professionals 
  There is no any approved policy on 
clinical guidelines. However, it is 
valued by SCDMTE and, currently, 
by MoH. In early 2000s around 40 
clinical guidelines were developed 
under supervision of SCDMTE, 
however some are already obsolete. 
Problem-based training in 
pharmacotherapy in 
undergraduate training 
  There is no special policy, however 
problem-based training is provided 
(Armenia Pharmaceutical, 2010) 
Continuing in-service 
medical education as a 
licensure requirement 
Continuing education is required, however 
not as a licensure requirement, as there is 
currently no licensing system for health 
professionals in place 
RA Government Decree N 
867 of June 29
th
, 2002 of 
29.06.2002 on “Rules on 
Licensing Production of 
Medicines, Pharmacy 




Practice, Health Service, 
Implementation of 
Medical Professional 
Education Curricula, as 
well as on Approve of 






Independent and unbiased 
medicine information 
Issue of medicine information is slightly 
covered by  
Law “On medicines” 






Two Formularies (containing 
unbiased medicine information, not 
just lists of medicines) were 
prepared by SCDMTE staff and 
published, the latest in 2010.  
Public education about 
medicines 
  There is no special policy. SCDMTE 
sometimes implement public 
education campaigns. 
Avoidance of perverse 
financial incentives to 
prescribers and dispensers 
  There is no special policy. 
Unfortunately, in practice such 




Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Operational research in 
medicine access, quality and 
rational use 
  There is no such policy, some 
organization initiate such research 
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Drug development and 
clinical research 
There is special policy on clinical trials.  RA Law “On medical aid 







 (in Armenian) 
 
RA Government Decree N 
63 of January 24
th
, 2002 
“On Rules on 
Implementation of 
Clinical trials of new 




&langid=2 (in Armenian) 
 
RA Minister of Health 
Order N 05-N of 17 May, 
2011 “To approve the list 
of required documents for 
obtaining authorization to 
conduct clinical trials and 





Approved requirements only partly  
cover set of requirements suggested 
by the majority of GCP rules  
 




Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Government responsibility 
for planning and overseeing 
the development, training, 
team building and career 
planning of human 
resources needed for the 
pharmaceutical sector 
There is a policy on licensing 
implementing Medical Professional 
Education Curricula 
RA Government Decree N 
867 of June 29
th
, 2002 of 
29.06.2002 on “Rules on 
Licensing Production of 
Medicines, Pharmacy 
Practice, Health Service, 
Implementation of 
Medical Professional 
Education Curricula, as 
well as on Approve of 







There is no special policy on 
development human resources for  
the pharmaceutical sector  
Definition of minimum 
education and training 
requirements for each 
category of staff 
There are certain requirements on 
education for those who is implementing 
pharmaceutical service.  
See above-mentioned RA 
Government Decree N 
867. 
 
The need for external 
technical cooperation 
(national and international) 
  There is no policy approved, 
however, there is an active 
cooperation with the WHO Special 
Project for 
 
Pharmaceuticals in NIS at the WHO 




Monitoring and evaluation 
 
Key policies suggested by 
WHO 
 
Policies existing in Armenia Corresponding 
document and its link 
Notes about policies that are not 
approved or do not exist 
Explicit government 
commitment to the 
principles of monitoring and 
evaluation 
  There is no any policy on 
monitoring and evaluation 
Baseline survey of the 
whole country carried out 
early in the implementation 
of the policy 
  Never implemented by authorities. 
Some survey were implemented by 
NGOs with funding of International 
organizations 




  The one-time assessment (not-
indicator-based) was initiated by 
SCDMTE in 2001. 
 
An indicator-based assessment was 
carried out by NGO called “DURG” 
in 2002 
Independent external 
evaluation of the impact of 
the policy on all sectors of 
the community and the 
economy, preferably every 2 
to 3 years 




Many important key policies were introduced through provisions for the Law “On 
medicines” of 1998. The law covers the following areas: pharmaceutical activity and its 
licensing, manufacturing, labelling, import and export, information, advertisement, destruction, 
registration, quality assurance, state guarantees of medicines ensuring to population and some 
others. However, all policies which are stated there, describe the main approaches very briefly - 
in one or few sentences.  According to this law more than ten regulatory documents should be 
developed and introduced by the Government and the Ministry of Health in order to provide 
detailed requirements and procedures. Only some of these exist as drafts (labelling, state 
guarantees of medicines ensuring to population and some others).  
The results of this assessment also show that the number of policies introduced in the 
different components varies (Table 2). The best ratio of approved to recommended policies is 
observed in the area of Regulation and Quality Assurance (5 of 7) while the no policies have 
been developed on Monitoring. Only a few policies are available in the fields of Affordability 
and Rational Use. This is especially alarming because a lack of access to medicines and 
inappropriate use are among the most important challenges in Armenia.  
Although a special policy on antibiotics was not included in the list of key policies used for 
assessment, it is necessary to mention that this area currently cause a great concern however is 
not covered by any policy or regulation document. 
The results of this assessment concerning differences in numbers of approved policies among 
the various components are consistent with the opinion of a key informant from Armenia who 
indicates that introducing systems ensuring quality and safety of medicines is a strength of 
Armenia’s policies while the absence of systematization and interlinked activities especially 
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among those aimed to provide access to medicines and improve rational use are the weaknesses 
of pharmaceutical policy in the country. 
Table 2. The number of key policies on pharmaceuticals approved in Armenia, by 
components 
 





































5 (1 of 5  is 
not applicable 
for Armenia) 
2 0 2 (1 –partly) 2 
Affordability 4 1 (not specific 
for medicines) 
0 0 1 
Financing 
options 
6 3 2 (mainly) 1 0 
Supply 
System 




7 5 2 3 1 
Rational use 7 2 0 2 3 








4 0 0 0 2 
 
The uneven policy development can be explained by numerous factors, in particular by 
differences in attention paid by policy-makers and input received in development of various 
components. The higher ratio of approved to recommended policies in the sphere of  regulation 
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and quality assurance can be explained  by (1) the large input provided by SCDNTE to this field, 
(2) the tradition established in early 90s and then supported by the MoH and the Government that 
registration and import require a strong legislative basis, (3) the fact that these issues were very 
technical and it became possible to provide a relatively broader coverage for them in the Law 
“On medicines” while other more understandable components have caused more disagreements 
between stakeholders and were extremely shortened in the law’s text, and (4) the fact that the 
SCDMTE’s political power was greater than of many of their opponents.  After its creation in 
1992, SCDMTE became the Centre of Excellence that employed highly qualified and motivated 
professionals who started to develop policies and rules in order to be able to carry out their 
routine functions. Because at that time the country needed to have its own independent system of 
registration as soon as possible it was developed and introduced very rapidly. High professional 
competence of the staff, a motivation to provide patients with quality medicines, and technical 
cooperation with WHO made it possible to introduce systems which were able to assure the 
quality of registered and imported medicines. As an organization responsible for implementing 
regulatory functions, SCDMTE became interested in having an approved legislative basis for its 
activity and certain regulatory documents were developed and approved. Being rather technical 
and based on the Law’s requirements these documents faced minimal opposition and were 
accepted by decision-makers quite rapidly. It is also important that as a state joint-stock company 
funded from registration fees, SCDMTE has been able to finance activities it is interested in, 
including hiring staff it needs.  
Other policy components, in particular affordability and rational use, have not become 
priority issues although everyone understands that these are significant problems. A general 
approach was that people in poor country (even now when Armenia became a low middle-
 54 
 
income country) cannot afford medicines. For a long time policy-makers have not thought that 
although Government cannot provide access to medicines at the level that high-income countries 
do, it can improve the situation by introducing some cost-effective strategies which are able to 
save money and improve performance. Because the Ministry of Health is generally responsible 
for health policy in the country and policy on medicines is an integral part of health policy, it 
would be logical to suppose that the Department of Pharmaceutical Policy in MoH is responsible 
for this issue. Unfortunately, this Department has not usually had the necessary human resources 
to develop policy suggestions. The Department consists of only a few people and has been 
focused on its routine functions mainly related to managing some medicines supply issues 
(donations, centralized procurement, etc.).  
Although no single organization is formally responsible for rational medicines use it has been 
promoted by the SCDMTE for a long time. A lot of work was done by them separately and in 
collaboration with experts from other health care organizations to develop Standard Treatment 
Guidelines (about 40 were approved and published). In addition, two National Formularies were 
developed and published and drug and therapeutic committees were established in many medical 
organizations. These activities were implemented as initiatives not supported by any legislative 
basis. SCDMTE cannot draft regulatory documents containing appropriate policies these 
documents would not be supported by existing legislation. 
Thus, it can be said that two important challengers in the pharmaceutical sector, affordability 
of medicines and their rational use, have not received necessary attention and are poorly 
addressed. Developing and implementing a comprehensive NMP would require that the main 
challenges are carefully and equitably considered and addressed, appropriate strategies are 
identified to achieve defined objectives and responsibilities are clearly stated. 
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5. Pharmaceutical policy process in Armenia 
There are different models of the policy process. One of them is the “stages model”. This 
model (Figure 1) suggests that the policy process proceeds step by step starting from “Issue 
emergence”, then it reaches agenda and so on. The results of evaluation provide feedback after 
what it starts again. This model was criticized, in particular, because not every idea passes the 
stage of “Agenda Setting” and, thus, some ideas do not reach further stages, or because 
implementation and evaluation stages cannot be separated (Birkland, 2011). Nevertheless, this 
model seems to be the most suitable for describing policy process, in particular, pharmaceutical 
policy in Armenia. It is also the closest to approaches suggested by WHO for NMP process and 
by Roberts & Reich (2011) for pharmaceutical reforms. 
Figure 1. The Stages Model of the Policy Process 
Issue 
emergence 









    
 
Source: Birkland, 2011 
Step 1- Issue emergence.  
During this stage different public problems emerge in a society (Birkland, 2011). In Armenia 
there are still many small and big problems in the pharmaceutical sector that emerged in 90s and 
are well-known for many years. The specific difference in the pharmaceutical policy process in 
Armenia is that in the majority cases the policy process starts not from issue emergence but from 
the problem’s solution emergence, for example from submission of a draft of policy or 
regulatory document developed by any reformer to MoH.  Pharmaceutical policy ideas were 
developed in Armenia by different initiators. In 1992, the first pharmaceutical policy ideas were 
 56 
 
initiated by individuals. After SCDMTE was established, policy ideas were made mainly by this 
institution where the majority of reformers were employed. In 2000s, SCDMTE’s staff was 
developing drafts of sub-legislative documents and then presented them to the Ministry of 
Health. Few policy proposals were developed and presented to MoH by the NGO “Drug 
Utilization Research Group”.  Some proposals were initiated by MoH. Drafts of sub-legislative 
documents (on Good manufacturing practice, labeling, a new system of registration) have been 
developed based on the analogous documents of EU. 
The most recent policy development that led to approval of a program to address certain 
pharmaceutical policy problems in 2012 was initiated very differently. The problems related to 
medicines were pointed out by the President and the policy development process started in the 
MOH after direct instructions to improve the situation from the top policy officials - the 
President and the Government (Dumanyan, 2012). 
Step 2 – Agenda Setting 
The great majority of ideas (proposals) reached the agenda (meaning that proposals gain 
sufficient attention from state officials, at least at the MoH level). The majority of 
recommendations/drafts have been considered and discussed at least for some time. For example, 
a draft of the Essential Medicines List for Children submitted by DURG is currently actively 
under consideration in the MoH and SCDNTE.  
Step 3 – Alternative selection 
Proposals are generally submitted as drafts of policy or regulatory documents, not as a policy 
papers suggesting different options. Alternative selection has been mainly made between three 
choices: to focus on adoption and implementation of policy/regulation (this includes its 
approval), to start considerations, or do nothing. The second decision was quite popular. The 
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interesting example is the List of EML. Until 2007 it was updated every 2 years and each new 
version was issued as a Decree of the Minister of Health. The last version developed by 
SCDMTE in 2009 and submitted to MOH has been under consideration so long that has become 
obsolete. Currently a new version of EML has been developed by SCDMTE and will be 
submitted to the MoH very soon.  
Step 4 – Enactment 
Only parts of policy proposals have been enacted. Some proposals have been discussed 
effectively and soon became policies (for example, GMP requirements in 2010). Some drafts 
were under consideration for a very long time and have not been a priority among other 
competitive tasks for a particular official, or because the consensus has not been reached, or 
because the administration has changed and a new one was not interested (for example, a Draft 
of Decree of the Minister of Health “On approval of Rule and conditions of narcotic and 
psychotropic substance use for medical purpose” appeared in the late 2000s, has not been passed 
yet and, it seems, even is not actively discussing). Some drafts were considered for years and 
have not been accepted due to technical reasons (regulation on labeling has not been approved by 
the Ministry of Justice due to various reasons and, finally, because of discrepancy between its 
title and provision in the Law “On medicines”).  
Step 5 – Implementation 
Approved documents that cover issues related to medicines evaluation, quality and safety 
have been developed by SCDMTE. These policies are generally implemented very well as 
drafted. However, even in the cases when SCDMTE does not agree with the decisions approved 
by the authorities, the staffs strongly follow them. For example, some changes on import rules 
initiated by local wholesalers and approved by the Government in 2011 have been not welcomed 
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by the SCDMTE staff, however new rules are strictly implemented. However, some provisions 
clearly stated in the law have been never implemented in the private sector. For example, all the 
prescription-only medicines (excluding those containing narcotic and psychotropic substances) 
are dispensed from pharmacies without prescription although it is not allowed by the Law “On 
Medicines”.  Another example is the policy to prescribe medicines from EML to out-patients 
who receive medicines in retail pharmacy free of charge or with privileges; nevertheless, almost 
half of prescribed medicines are out of EML (Melikyan, 2011). 
Step 6 – Evaluation 
In Armenia there is no the system of monitoring and evaluation of pharmaceutical policy 
(Armenia Pharmaceutical, 2010). Individual pharmaceutical policies introduced by MoH are 
usually not monitored or evaluated.   
6. Effectiveness of the pharmaceutical policy process in Armenia 
Effectiveness of the pharmaceutical policy process in Armenia can be assessed according to 
process and outcome indicators developed and presented in the Background. The results of 
assessing policy process for selected policies are presented in the Table 3. The following four 
policies were chosen: those which have led to developing a draft of NMP in 2003 and a draft of 
new Law “On Medicines”, as well as to approval of the Government Decree “Rules of Good 
Manufacturing Practice” (2010) and the Decision of Government meeting “On approval of 
program on solving problems in state control in the area of Health care, as well as in 
pharmaceutical policy; and list of measures ensuring implementation of program” (2012). These 
four policies were selected because of the following reasons: the first two documents are the 
most important ones for the country (national overall pharmaceutical policy and national law on 
medicines) however, although drafts were developed long ago, they are not approved yet; the 
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second two policies were recently developed and approved during a short-lasting policy process 
although they cover only certain issues in the pharmaceutical sector.  
It is seen from the table that PPP in Armenia has some strengths and weakness (strengths are 
those activities for which appropriate indicators in the table get positive respond). Examples of 
strengths are the following:  international experience is taken into account when developing a 
draft; also, drafts are mainly widely circulated for consideration with stakeholders. At the same 
time, an evaluation system is never used and this is an important weakness of policy processes in 
the country.  
Based on the data in the table it can be said that PPP in Armenia is not effective because 
process often do not reach its outcomes – well developed and actively discussed drafts of policy 
documents are not approved without any clear reason, plans for implementation of those that 
were approved are conducted only partly and evaluation is never done.    
Data in the table suggest that drafts of policy documents are approved only when there is 
political will/commitment at the Government level or the National Assembly level. Such 
political will/commitment can be provided/rejected due to various reasons. On my opinion, the 
main general reasons of a lack of political will related to medicines issues in Armenia are the 
following: common wrong assumption shared by officials and the public that in a country with 
restricted budget access to medicines cannot be improved significantly, so there is no need to 
make efforts; medicines are not considered to be a priority among other pressing Health care 
problems.  In two cases (examples) presented in the table 3 policy support was provided because 
at the time of approval these problems were widely considered in media, policy-makers were 
interested to demonstrate their readiness to implement social reforms and there were no strong 
opposition for such new policy among powerful stakeholders. It can be assumed that among 
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three necessary for policy window streams suggested by Kingdon (2003) – streams of problems, 
policies and politics, politics is probably the most valuable in Armenia because problems exist 
for a long time, solutions are suggested time to time (drafts of proposal), however due to lack of 
favorable political sources policy proposals do not became active. At the same time, when there 
are certain happenings in policy stream (for example, changes in the Ministry/Government or 
elections are expected), the Government becomes very active, makes social issues priority and 
provide political will/commitment at least for some time. The new Minister of Health initiated 
operative research in the pharmaceutical field; in addition, the President has paid more attention 
to health and pharmaceutical issues during his reelection campaign. All this has led to rapid 
development and approval by the Government of a new program addressing some problems in 
the pharmaceutical sector and also developing a new draft of a new Law “On Medicines” that is 
currently considered by the National Assembly. Thus, opportunity window that existed in 2012 
created conditions for some positive changes at the Government level (approval of program, 
pushing a draft of law to the National Assembly). However, at present it is not clear whether the 
National Assembly will demonstrate enough political will/commitment and whether a new draft 
will be passed by the National Assembly, and even if so – when and with which deletions. The 
reason is well known – difficulties in reaching consensus on some important issues because 
stakeholders have conflicting interests in this field and some of them have support in the 
Parliament; also, a draft suggests numerous changes and not all provisions seem to be evidently 
useful or implementable. Due to political will at governmental and parliament level these 
considerations can continue years and years. 
Thus, it seems that the most important factor influencing effectiveness of the pharmaceutical 
policy process in Armenia is political will/commitment. Without appropriate support any policy 
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proposal, does not matter how well-developed it is, will remain just good intent. It is important to 
identify and introduce strategies which could be able to improve political will/commitment 
regarding to the pharmaceutical policy in the country. In Australia consumers were at the heart of 
debate which have led to developing policy document (Walsh, 2011), however in Armenia there 
is no patient organizations and it would be naïve to expect that they will be founded and became 
strong in the near future; consumer organizations are relatively weak and have no enough power 
to press the Government. Creation of powerful advocacy coalition that would include many 
stakeholders which are sharing values and interests could be a more promising strategy. Such 
Coalition could support patient’s interests, and be much more influential due to involving 
professional organizations (which can always provide expertise), consumer and other NGOs 
(including international NGOs), political activists, representatives of media and other interested 
stakeholders. 
Table 3. Process and outcome measures for the pharmaceutical policy process in Armenia  
(four examples) 
 
















Responsibilities for policy 
formulation are defined. 
No Yes Yes Yes 
Operational research is 
implemented to provide 
baseline data  
Yes No Yes Data were 
available from 
other sources 
International experience on 
policy strategies is studied. 
Yes Yes Yes Unknown 
A policy paper on the issue 
considered is written and 
presented to policy-makers 
(should include brief description 
of the current situation, 
evidence based policy options). 
Yes No Yes No 
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Stakeholder analysis is 
implemented. 
No No Yes No 
Government or National 
Assembly commitment is 
ensured. 
No No Yes Yes 
Draft of a final document is 
presented (if it is a policy 
document it should include 
goals and strategies to achieve 
these goals; if it is 
legislation/regulation document, 
it should include appropriate 
provisions). 
Yes Yes Yes Yes 
Draft is made publicly 
available. 
No Yes Unknown No 
A national conference/meeting 
is organized to present the final 
draft (all stakeholders including 
patient/consumer organizations 
as well as media are invited). 
No No No No 
Draft of Implementation plan is 
presented. 
No No Yes Yes 
Draft of evaluation system is 
presented  
Yes No No No 
Drafts are circulated for 
consideration. 
Yes Yes Partly No 
Funding is provided. 
 
No No Partly (for 
regulation 
by the State) 
No 
Draft of Implementation plan is 
formally approved. 
 





Draft of evaluation system is 
formally approved  
No N/A No No 
Outcome measures 
 
    
Stage of Formulation: 
document is formally approved. 
No No Yes Yes 
Stage of Implementation and 
Monitoring: All activities in the 
Implementation plan are 
implemented. 
- - Partly Partly 
Stage of Implementation and 
Monitoring: The final 
evaluation is made and 
distributed. 
- - No No 
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7. Strengths and weaknesses of the pharmaceutical policy process in Armenia 
This brief description of the pharmaceutical policy process in Armenia, the information 
presented in the case study (see below) and the previous sections indicate that there are important 
strengths and weaknesses in the Armenian pharmaceutical policy process.  
Box 2. 
Case study: Draft of a new Law “On Medicines” 
Very soon after approval of the Law “On Medicines in 1998, it became evident that this first document did not cover 
many necessary issues (for example, functions of a Drug Regulatory Authority, a system of ensuring affordability of 
medicines) and, correspondingly, did not provide a reliable legislative basis for the Armenian pharmaceutical sector. 
It was clear that the country needed a new law providing more detailed provisions related to medicines and 
pharmaceutical services. A draft of a new law “On medicines” was formulated by the SCDMTE in 2003 and 
submitted to MoH for consideration. Many corresponding regulatory documents which suggest policies for different 
components of the Pharmaceutical sector have also been developed in order to be considered after approval of a 
Draft.  
After being reviewed at the MoH level a Draft was submitted for the Government consideration and then – to the 
National Assembly (Armenian Parliament). It was widely discussed with involving numerous stakeholders: 
pharmaceutical associations, local industry, academia and so on.  Considerations in the National Assembly (NA) 
have not been completed until its term of office for the acting was expired. In further years a draft was many times 
considered at the different levels: MoH, Government, NA, however, has not been passed yet.  
 
Another draft of new Law “On medicines” was developed by SCDMTE in 2012 after Government’s decision that a 
new Law should be prepared. This new draft was submitted to MoH and became available for comments being 
presented at the MoH official web site. Comments were collected until December 2012, then they were carefully 
reviewed by SCDMTE and appropriate changes were made. Currently this draft is considered by the National 
Assembly. Thus, it can be said that a draft of new law “On medicines” is at the policy agenda already 10 years. 
 
This new draft covers the following aspects: regulation, principles of state policy, a state system of ensuring 
medicines affordability, a system of medicines provision free and with privileges,  price regulation, drug 
development, clinical trials,  registration, adverse drug reactions monitoring, manufacturing, packaging, labelling, 
import and export, transportation, storage, distribution, information, advertisement, inspection. Numerous regulation 
documents providing detailed interpretation of Law’s provisions will be introduced soon after approval on a new 
law. 
 
The most harmful effect caused by delay in approval of a new Law “On medicines” is impossibility to consider and 
approve numerous regulatory documents required by it. Both old and new drafts include numerous provisions 
requiring approval of regulation documents covering the most important policies in the pharmaceutical sector. The 
majority of these requirements is not included in the existing Law and, correspondingly, sub-legislative documents 
cannot be issued.  Uncovered documents include such vital issues as the state system of ensuring affordability of 
medicines and price regulation.  
 
Strengths 
1. There are some organizations in Armenia in addition to MoH which are interested and 
capable to develop policy proposals including drafts of policy and legislative documents. 
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These organizations are able to move issues to policy agenda. SCDMTE is a very strong 
institution that has relatively good funding and human resources; it is able to develop 
drafts of legislative/regulation documents especially those which would serve as a basis 
for providing effectiveness, safety and quality of medicines. 
2. Policy proposals are mainly well prepared and ready for considerations; the majority of 
them take into account International experience, recommendations of WHO, local 
conditions.  
3. Many stakeholders are involved in a process of policy and regulation drafts consideration 
and have a chance to defend their opinion. 
4. Drafts of the main legislative documents are available at MoH’s official web site and any 
written comments on drafts can be submitted to MoH. 
Weaknesses 
1. Problems are rarely considered and/or addressed by state officials themselves; instead 
these officials consider ready proposals which could be seen by them not as a priority. 
An important exception is the situation in 2012 when certain problems were 
recognized and certain promises (Sargsyan, 2013) and decisions (Decision, 2012) were 
made. Other examples of initiatives which came from officials include those when  the 
MoH staff drafted a policy on creating cost-effective mechanism for reimbursement in 
2005, formulated rules on transportation and storage of medicines in 2010 and made 
couple other suggestions. These cases make a small but the most successful part of 
policy developments, because the proposals were rapidly discussed (if discussed at all) 
and approved. It seems that emerged interest to issue and support from decision-
makers plays the most important role in the Armenian pharmaceutical policy process. 
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Problems may exist for a long time, be moved to policy arena, however, real steps to 
solve them are made mainly when a political will is provided. 
2. Although policy consideration is an important and positive process, it is clear that 
policy-makers in Armenia have difficulties reaching consensus. Stakeholders in 
Armenia, like everywhere, have competing interests related to medicines, and this 
causes delay in approval of extremely important documents like it happened with a 
draft of Law “On medicines”.  
3. Although many stakeholders are involved in policy deliberations, they have very 
different political power and, correspondingly, are able to defend their interest with 
very different success. For example, wholesalers were able to convince the 
Government to make some changes in rules on import although it may compromise the 
quality assurance system. The weakest stakeholder in the country is 
patients/consumers. There are no patient organizations in Armenia due to certain 
reasons: absence of such tradition; a small population and, appropriately, relatively 
small number of patients with the same disease; many patients are poor, fighting for 
survival and do not have time and knowledge to create or be involved in voluntary 
activities, a lack of trust in effectiveness of a public activity. Consumers’ organizations 
are poorly educated and not active in the area of the pharmaceutical policy. The 
patients’ interests are presented by state officials but these are among other competing 
interests. Some professional associations and representatives of Academy try to defend 
patient’s interest, however, these stakeholders have a little political power and, 
correspondingly, often ignored. Those organizations which are most interested in 
promoting affordability of medicines, their safety and rational use are often not 
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involved in policy discussions and, also, do not have any funding to support their 
activity in this area.   
Part II. Pharmaceutical policy process in Newly Independent States 
There are limited data on the pharmaceutical policy process in NIS. Unfortunately, it was 
impossible to find studies examining and analysing the direct outcomes of a NMP document 
approval. Although NMP are approved in many NIS, they are rarely monitored and the results 
are not published. In addition, it probably would be very complicated task to assess the role of 
having approved document because numerous other factors also influence the final results in 
very rapidly changing political, social, economic environment in these countries during the last 
20 years.  
The only publication available that presents the results of study intended to assess a role of 
NMP implementation in NIS, is one that covers four countries from the Middle Asia region – 
Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan (Nurgojin, 2004). Based on the data 
collected mainly through interviewing key persons in mentioned countries authors have 
concluded that certain elements of NMP recommended by WHO were observed in all the 
countries studied; in Kyrgyzstan the concept of NMP was introduced more widely and the level 
of availability of medicines was higher. 
Thus, due to lack of data on evaluation of NMP outcomes in NIS, only important elements of 
the pharmaceutical policy process itself have been examined and are presented here: existence of 
formally approved NMP document and implementation plan, its monitoring and evaluation, 
involvement of stakeholders. Some data are summarized in Table 4. 
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Table 4.   National Medicines Policy documents in Newly Independent States  
Country Formally approved 
NMP document  
Data of 
approval 
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1. Existence of NMP document  
The data available indicates that NMP document has been formally approved in the majority 
of NIS (eight of twelve). NMP is mainly available as a document, in one case (Georgia) – a part 
of a document. In five countries (Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan) 
officially authorized document has the name including the term “medicines policy”, in two 
countries (Belarus and Russia) – “concept of medicines supply”. In one country (Georgia) – 
NMP is a part of the approved “National health policy” document. In six countries the current 
NMP has been authorized at a high level as a formal document: in four - by the Resolution of the 
Government/Council of Ministers, in one (Moldova) – by the Parliament and in one (Georgia) – 
by the Ukase of the President*. In three countries (Russia, Tajikistan, Uzbekistan) it has been 
approved by the Ministry of Health.  
  In many of the countries documents having a various status and name but in fact being a 
written description of comprehensive NMP, have been approved soon after independence. 
According to WHO data, nine countries have approved NMP still in the first five years 
(Saoutenkova, 2003). Recently the significant changes in situations alongside with understanding 
of that many problems have not been solved yet, have led to renewal of the interest to a 
medicines policy. Russia approved its document in February this year, Kazakhstan and 
Kyrgyzstan have developed drafts of new NMP in 2011 and 2013, correspondingly, and these 
documents are currently under consideration. In May 2013 Kyrgyzstan developed the Second 
draft that is intended for 2014-2020 (Kyrgyzstan 2
nd
 Draft, 2013). 
Analysis shows that some countries formulate and approve a new NMP when they consider 
their existing document to be obsolete. Thus, the last authorized NMP document in Kyrgyzstan is 
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already the third one and Kyrgyzstan formulated a draft of the forth document for the period of 
2014-2020; in Kazakhstan and Moldova the last approved document is the second one.  
The interesting lesson from countries experience is that in the several countries (Kazakhstan, 
Kyrgyzstan, Moldova) where NMP has been initially approved at a level of Ministry of Health or 
as administrative document during advisory meetings, the further version of NMP has been 
passed as an official document (Kazakhstan, Kyrgyzstan) or at higher level (in Moldova the last 
document was approved by the Parliament). Existence of a document with the official status 
allows a higher level of performance and authorization by the Government/Parliament of the 
country allows the involvement of all the necessary sectors simultaneously. According the 
opinion of key informant from Russia, the document was approved by the Health Ministry but 
not by the Government (as was originally expected), so in fact it is not a National Strategy, but 
rather an internal ministerial paper. 
2. Formulating NMP 
Formulating NMP in NIS took place in the certain degree according to the recommendations 
of the WHO. This is the result of the activity carried out by WHO, especially by the Regional 
Office for Europe from the beginning of 90s. Organization of a process of formulating a NMP 
document was carried out mainly by the Ministry of Health/corresponding departments or 
Medicines Regulatory Authorities. In many cases drafts of documents have also been prepared 
by the MoH/corresponding departments, for example in Belarus, Georgia, and Kyrgyzstan. In 
Moldova, for example, a draft has been prepared jointly by the National Institute of Pharmacy, 
the Pharmaceutical faculty of the State Medical Pharmaceutical University named after Nikolay 
Testemitsanu and the MoH, Republic Moldova*. Document in Russia was prepared by MoH 
(key informant from Russia).  
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There is a lack of the information on whether development of documents has been based on 
an analysis of the situation. In the Kirghiz Republic, for example, formulating a draft of the 
second NMP document was based on assessment what was carried out with use of a set of the 
WHO indicators. According the opinion of key informant from Russia, the document adopted by 
MoH in February was not based on sound situation analysis and was not comprehensive, in 
particular,  practically does not include plans for strengthening of the medicines regulatory 
system - the only indication was “international harmonization” . 
Involvement of the interested parties, in particular, representatives of a legislative bodies, 
various ministries, departments, universities and so forth in discussions on a draft of a NMP 
document is noted in nearly all the countries. The example of Kazakhstan is interesting. As it 
was already mentioned, at the beginning the document “State policy in the sphere of medicines 
circulation” was approved by the Pharmaceutical section at the Conference in 2001; then in 2002 
this document was published in the professional newspaper and journal in order to provide a 
wide involvement of interested parties in discussions. The suggestions submitted, for example, 
those suggested by the head of a professional nongovernmental organization, were published in 
the same newspaper (Berkman, 2002). Nevertheless, it is obvious, that almost everywhere the 
number of participants involved in development/discussion of a NMP is limited. Examples of 
cases of involving consumer or patient organizations, or other non-professional NGOs in 
pharmaceutical policy process have not been available in publications. Involvement of the public 
professional organizations in a process of NMP development is also limited. On the other hand, 
the professional community in some countries come with very serious initiatives on the issues 
connected to a medicines policy. An interesting example is approval of the document “Concept 
of developing the pharmaceutical sector” at the VI National congress of pharmacists in Ukraine 
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in 2005 (The concept, 2005). In Russia necessity of developing a NMP document and also 
possible approaches to its formulating have been actively discussed and moved ahead by leading 
experts (Meshkovsky 2000, Beregovikh 2005), presented at various conferences and sessions of 
public organizations, round tables, and also in professional publication. The Chamber of 
Commerce and Industry of Russian Federation of the Russian Federation has played an active 
role (RF CCI, 2004). 
 Today, in the NIS there is a significant number of public professional organizations 
involving many qualified and interested professionals. Although they basically have no 
significant experience participating in the pharmaceutical policy process, this huge potential of 
professionals can and should be involved in formulating and discussing drafts of a NMP. It is 
difficult to overestimate the contribution the army of professionals can bring to development of 
the pharmaceutical sector of their countries.   
Countries have not organized active campaigns on launching NMP but in some of them the 
information about approval of the document was published or presented in the Internet, 
especially those approved in the last 10 years. For example, a detailed information about signing 
the Resolution of the Governments of Kyrgyzstan on КР NMP for 2007-2010 was submitted on 
16
th
 January, 2007 on the State Internet portal site; the article contains certain details of the 
document including the main observations and tasks. There is an access in the Internet to the full 
text in Russian of NMP documents of Belarus, Kyrgyzstan, Russia, and Tajikistan. 
3. Implementing and monitoring NMP 
Although NMP documents are available in the majority of the countries, implementation 
plans based on the policy are developed only in some of them, including Belarus, Kyrgyzstan, 
Moldova and Uzbekistan. This has not significantly changed compared with the 1990’s when it 
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was also noted that most national drug policies lacked an operational implementation plan or 
adequate monitoring mechanisms (WHO, 1998). According to the WHO approach based on 
various countries’ experience, without the plan of implementation medicines policy process 
remains a dead document (WHO, 2001). Accordingly, it is important for NIS to not only pay 
attention to developing the NMP, but also to continue work to develop an appropriate 
implementation plan to concretize actions, responsibilities, budget, and other terms.  
It is also important to remember that implementation of NMP is a common task in which 
various ministries, the private sector and many other stakeholders are involved. Accordingly, 
coordination of actions, involvement of all interested parties to both formulating plans and their 
implementation and monitoring is necessary.  
The Ministry of Health in most countries cooperates with other state bodies and provides 
public relations. For example, in Kazakhstan, after setting up the Committee on pharmacy, 
pharmaceutical and medical industry in its semi-annual report to the MoH Board a wide activity 
carried out in this area was specified. Agreements related to issues of pharmaceutical products 
between the MoH and other ministries and sectors have been prepared visits to regions and 
meetings with businessmen, nongovernmental organizations have been carried out. Problems 
were discussed in mass-media, including TV, on constant basis (Pak, 2002). However, to obtain 
the best possible outcome from PPP, it is necessary that implementation activities be carried out 
by all participants according to the discussed and approved plans based on a NMP. 
For coordinating activity and also PPP monitoring a special division in the MOH could be 
expedient. In few NIS there are divisions/units responsible for medicines policy issues. In 
Uzbekistan, for example, there is “Centre of a policy of medicines and devices” of the MoH, the 
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main purpose of which activity is introduction and implementation of a strategy of the Ministry 
of Health in the field of the national policy on medicines and devices.   
In nearly all NIS, studying and assessing the situation in the pharmaceutical sector is carried 
out to some extent and the results are published in scientific journals, other professional 
publications, and also in mass-media, on official sites of the Ministries of Health and Medicines 
Regulatory authorities of the countries, etc. Certain information on implemented reforms and the 
strategy are also presented. Nevertheless, the qualitative and quantitative data usually are not 
related to NMP or a plan of implementation’s contents. Such data indicate some achievements 
and problems in the pharmaceutical sector, but do not provide the opportunity to carry out 
monitoring and evaluation, and, accordingly, to draw a conclusion about progress in achieving 
the NMP goals and objectives. According to the WHO, although quality evaluation is useful, it 
cannot replace the need for quantitative measurement of the factual data. Use of the fixed 
package of indicators is necessary for ensuring that repeated and compared monitoring can be 
carried out (WHO, 2004).  
4. Factors influencing NMP 
Political will. In a number of countries (Belarus, Kazakhstan, Kyrgyzstan, Moldova) 
NMP documents have been developed by corresponding departments of the MoH or Medicines 
Regulatory Authority with participation of the MoH, and then have been authorized at a level of 
Resolution of Government/Council of Ministers and even the Parliament (Moldova) that clearly 
demonstrates commitment and suggests the level of political will of the country’s authorities to 
improve the situation in the pharmaceutical sector. Some countries specify the political will of 
authorities. For example, in Uzbekistan it is considered, that a dynamic development of the 
pharmaceutical sector in many respects was the result of explicit decisions by authorities of the 
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Republic, and in particular, the State joint-stock concern "Uzpharmsanoat” to support the 
development of this sector. Also, a number of the governmental decisions supported the 
establishment of a local pharmaceutical industry. Nevertheless, there is a lack of political will in 
many countries. In Russia, where the concept of NMP has been actively promoted by a number 
of leading professionals and organizations, an appropriate document appeared only this year. In 
the majority of countries the political will of the government was enough for documents 
approval; implementation plans have not been developed and/or systems of monitoring and 
evaluation have not been introduced, however. 
Support and the technical assistance from WHO. The majority of the countries specify 
support and the technical assistance of the World Health Organization. Administration of the 
pharmaceutical service in the MoH of the Kirghiz Republic notes that the development of a NMP 
started in 1994 at the advisory meeting with the WHO experts participation, and then, in 2001 
the evaluation of NMP introduction was carried out with the methodological support of WHO 
and based on the results of NMP implementation for the period of 1994-2000 a new draft was 
developed (Kurmanov, 2006). Support from the WHO Regional Office for Europe on issues 
related to formulating and implementing NMP is noted also by representatives of Kazakhstan 
(Kulakhmetova, I. 2000) and Tajikistan (Isupov, in press). Publication in Russian and English of 
the strategic document “The patient in Focus. A Strategy for Pharmaceutical Sector Reform in 
Newly Independent States”, prepared by the WHO Regional Office for Europe and the WHO 
Action Programme on Essential Drugs has provided an important methodological assistance. 
“The publication describes pharmaceutical sector reform in the newly independent states and sets 
out strategies for its further development. This global strategy will function as a guideline for 
further reform at country level” (WHO, 1998). Numerous consultations, seminars and other 
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support intended to increase a level of knowledge of countries’ experts in this sphere have been 
also carried out. A fortnight training seminar organized in 2002 in Tashkent should be noted 
along with other presentations in the area of NMP, including the special lecture "Process of a 
medicines policy”.  
Existence of resources. In many NIS there are insufficient resources for NMP 
implementation. In the opinion of the expert from Moldova, for example, the absence of a state 
financing intended for introducing NMP is the main weak link in their NMP
*
. According to the 
data available* in many countries special funding for introduction of NMP has not been planned. 
It is important to note, that in Kyrgyzstan where the pharmaceutical policy process is organized 
better than in many other counties of the region (e.g. an updating of the document on a regular 
basis - each 4-5 years, regular approval of appropriate implementation plans, monitoring 
according to indicators), a special financing on implementing a policy in the sphere health care 
has been allocated (the credit from the World bank)
*
. Absence of a specially allocated budget 
seems to be an important barrier influencing an active implementation of NMP in other NIS.  
Human resources. Numerous highly skilled professionals are employed in the NIS by 
different public and private organizations. In many cases individual experts and institutions 
initiate and support issues related to NMP. In the early 90’s professionals from the countries of 
the former USSR heard the term “NMP” for the first time. Due to support from the WHO the 
concept of NMP has quickly spread in this region; however, initiatives of the countries were also 
very important. Ukraine and Kazakhstan, for example, have published the important materials 
including translation into Russian of the last WHO guidelines «How to develop and implement a 
national drug policy in their main professional editions. However, there are certain factors 
connected to human resources which will influence PPP: insufficient number and, accordingly, 
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excessive overload of officials by routine activity; need to solve at once many unresolved 
problems in the pharmaceutical sector, including improving legislation; a low motivation due to 
an inadequate payment; a lack of knowledge and experience in sphere NMP and a lack of access 
to the appropriate information; a lack of researchers and, appropriately, necessary data. 
Therefore, increase of a level of knowledge in the area of NMP and the pharmaceutical sector 
management remains an actual task. Increase of a level of motivation and responsibility and 
promotion of ethical standards among the experts involved in the sphere of management and 
regulation in the pharmaceutical sector also seems essential.  
5. Lessons learned from PPP in NIS 
Some lessons can be learned from the experience of NIS on developing and implementing 
pharmaceutical policy; these lessons can be useful for Armenian policy analysts and policy-
makers. 
1.  Having formally approved document of NMP can be considered to be useful for 
improving the situation in the pharmaceutical sector (eight of twelve countries have 
formally approved document, three of them have approved also the second one or 
developed a draft for approval;  in two of four countries where there is no formal 
document, NMP document has been approved by professional bodies and countries have 
been trying to have a formal document; all this suggests that NIS found out having a 
formally approved document to be useful). 
2. It is preferable to approve a NMP document at the governmental or higher level (in five 
of eight countries formal documents including the second/third ones were approved by 
Government, Parliament or President; new drafts in these countries are also intended to 
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be approved at the same level; this suggests that countries found out this high level to be 
appropriate). 
3. It is important to make a draft of NMP document publicly available and provide 
conditions for wide consideration with involving different stakeholders; it is also 
important not only collect suggestions, but also to take them into account (drafts of NMP 
documents considered and approved during the last decade were available through 
professional or other media; opportunity to submit comments was provided; it is unclear 
whether suggestions were taken into account, and there is opinion (informant from 
Russia) that comments were accommodated in an inconsistent manner). 
4. Due to absence of system of monitoring and evaluation countries are not able to evaluate 
their progress in the pharmaceutical sector even if they fix changes of some indicators 
(Kyrgyzstan is the only country among NIS that implements monitoring of NMP). 
5. Patients’ including consumers’ organizations are currently not able to make a difference 
in the pharmaceutical policy process in NIS, so it is important to identify an 
organizational framework that would be able to influence PPP in order to improve it and 
provide appropriate outcomes of the process and pharmaceutical policy. 
Part III. Discussion and recommendations on pharmaceutical policy process 
in Armenia 
Discussion 
The results of analysis of process and outcome indicators as well as other data presented 
in the Part I have shown that the pharmaceutical policy process in Armenia is not effective 
because it does not provide appropriate outcomes – the necessary law and regulation documents, 
policy documents and actions; correspondingly, not-existing policies cannot be implemented; 
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even those policies which are approved are implemented only partly and not monitored. The 
main reason can be lack of political will because other elements important for successful policy 
implementation and known constraints do not currently cause much concern as possible barriers. 
MSH (2011) suggests the following main constrains for successful NMP: lack of political will, 
lack of resources, opposition and corruption. Lack of resources that is always an important factor 
in middle-income countries is not an important barrier for formulating and implementing the 
majority of not-existing in Armenia but cost-effective policies in particular those addressing 
rational medicines use. It is well-known that there are many highly-qualified professionals in the 
country that could be involved in policy formulating and implementing, so lack of human 
resources is also cannot be considered as an important constrain. Opposition to pharmaceutical 
policy issues in Armenia is not very strong because different organizations have various interests 
even if they represent a single stakeholder, so they rarely join to defend their common interests; 
however, opposition is able to create barriers now because the Government and the National 
Assembly do not provide necessary political will and commitment (there are numerous strategies 
allowing to diminish or eliminate efforts of opposition which are currently not used). Corruption 
is considered to be very active in Armenia, and certainly can be a constrain for approval of 
certain policies and policy enforcement, however, if the Government would demonstrate 
appropriate political will through introducing transparency and accountability mechanisms and 
through evaluating policy implementation, corruption can be easily eliminated in the majority of 
areas dealing with medicines.  For example, some physicians ignore the rule requiring to 
prescribe medicines from the Essential medicines list to those patients who receive medicines 
free of charge, due to corruption. MoH could easily require reports from appropriate medical 
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establishments and analyze the situation. Being accountable, physicians would be afraid to break 
the rule and will stop to ignore it. 
Lack of political will and commitment is frequently met issue everywhere and rarely is 
provided sufficiently or for a long time. Phanouvong with co-authors (2002) identified that in 
four countries they studied the ministers of health and the cabinet played a crucial role in 
medicines policy initiation, however, once the policy was launched in Laos, Thailand and the 
Philippines a decrease in political will and commitment had occurred, and this had slowed the 
progress of NMP.  In Australia, where governments demonstrated commitment to continued 
funding of NMP, the policy was implemented more effectively.  
It is not easy task to improve political will in the country. It is considered that in 90s the 
development of the Australian NMP was the result of strong consumer (civil society) advocacy 
and lobbying (Robertson, 2012). Thus, we can assume that continuing government commitment 
was caused and supported by efforts of consumer (civil society) organizations and possibly this 
experience can be useful for other countries. Unfortunately, consumer activism in other countries 
(such as India, Thailand and China) was less successful due to a lack of financial support for 
consumer groups and poor access to policy makers. Summarizing the results of the Asia Pacific 
Conference on National Medicines Policies Robertson and co-authors (2012) concluded that 
“Consumer groups have an important role in ensuring policies are implemented.” (p.190), 
however engaging civil society to pressure governments to deliver appropriate medicines 
policies remains a key challenge.  
 Experience of Armenia and other NIS suggest that in this region patients/consumers 
groups are not sufficiently strong (for example, in Ukraine NMP document is not approved 
despite advocacy provided by consumer organizations), however there are many different other 
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NMP advocates such as academy, professional NGOs and associations. It seems that only joint 
efforts could be able to pressure the Governments sufficiently to provide appropriate political 
will and commitment on issues related to medicines. Advocacy coalitions involving different 
stakeholders having same interests and similar values at least on some important issues could 
provide enough pressure through evidence-based advocacy. Involved professional organizations 
could provide data and analysis of situation, consumer/patients organization could provide the 
results of case studies, media could be responsible for competent distribution of information, 
some partners could provide necessary funding to ensure financial sustainability of the coalition. 
Value of joint efforts was recently noted also at the Workshop “The role of NGOs in the 
development and implementation of National Medicines Policy” that was held in December 2012 
in Latvia (Workshop, 2012). Based on the results of discussion they arrived to various ideas 
including that “Those non-governmental organizations which protect the interests of patients 
should work together on problems where their opinions and needs are similar or identical, which 
would increase their chances of being heard and empower them (especially when it comes to 
organizations of patients).” MSH also supports such approach in its latest publication - 
“Mobilizing alliances and coalitions and creating constituents inside and outside the government 
are necessary to mobilize political will over the process” (MSH, 2011, p.4.5). 
 Based on the above-described approach I developed a pharmaceutical policy 
process framework involving advocacy coalition (Figure 2). Although this suggested framework 
has some similarities in main idea with the well-known Sabatier’s Advocacy Coalition 
Framework (ACF) – an important model of the policy process which is based on the idea that 
different interest groups can be organized in policy communities (Birkland, 2011), it is quite 
different in interpretation. In the ACF 2 or 4 advocacy coalitions can form a particular policy 
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domain joining around shared set of core values and beliefs. The framework suggested by me is 
developed particularly for PPP; it, correspondingly, includes coalition and those stakeholders 
which are typical for the pharmaceutical sector. Policy making in suggested framework is not a 
straight process like it is in ACF, but is a cycle because, the results of monitoring can reveal a 
new problem or because one policy cycle is not always able to solve problem completely - so 
policy cycle starts again. In the ACF policy process is influenced by two big groups of 
parameters – “relatively stable” and “external (system) events”. In the framework suggested the 
policy process is influenced by a coalition itself, other stakeholders in the sector, as well as more 
broadly by policy environment (policy environment: “The structural, social, economic, political, 
and other factors that influence and influenced by policy making”. Birkland, 2011, p.27). Policy 
process outcomes (laws, regulations, policies, etc.) are influenced by and influence the coalition, 
other stakeholders through PPP; and links between coalition and these outcomes are more 
numerous and more strong than between outcomes and separate stakeholders. These additional 
comprehensive links reflect additional opportunities of coalition to affect PPP and achieve policy 
process outcomes.  
Because a lack of political will is one of the most important constraints, but not a single 
reason of PPP ineffectiveness in Armenia, certain recommendations for the policy process 





Figure 2.  Framework of pharmaceutical policy process involving advocacy coalition 
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Recommendations for different stakeholders 
For the Government 
1. To create a Multi-sectoral Commission responsible for pharmaceutical policy issues; to 
ensure that the Commission consists of representatives of different stakeholders including 
organizations representing patients’ rights; to ensure an access of media to meetings; to 
ensure transparency of the commission’s activity. 
2. To create and introduce mechanisms for enforcement of existing legislation in the 
pharmaceutical sector 
For the Ministry of Health 
3. To implement comprehensive assessment of the pharmaceutical sector in order to get 
reliable data necessary for (1) defining  the main problems and their causes; (2) 
developing evidence-based policy; (3) providing baseline data for a further policy 
evaluation. 
4. To create a working group consisting of leading national experts and representatives of 
different stakeholders to develop a draft of a National Medicines Policy document that 
will include: goals (long-term and medium-term), tasks, strategies to achieve goals (for 
all selected components), sources of funding and timeline, a program of evaluation 
including indicators for monitoring outcomes; to select the following components: 
legislation, regulation, financing, pricing and reimbursement, supply, distribution, 
pharmaceutical care, rational use, antibiotics, controlled medicines, waste, research, 
human resources. 
5. To develop a draft of the five-year Implementation plan together with NMP (not after 
policy approval) and present it together with a policy document draft in order to provide a 
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clearer picture of further actions and expected results; to include in the plan the following 
information: activities, responsibilities, input, outcomes, timeline. 
6. To consider drafts with all the interested stakeholders during initially decided period of 
time (possibly 6 months), make changes based on presented comments and approve it as 
a Government Resolution. 
7. To create in MoH a special unit responsible for monitoring and evaluation of NMP; to 
create a Public Commission (involving representatives of patients’, consumers’ and other 
non-governmental organizations) to be involved in considerations of the results of policy 
monitoring and evaluation; to provide transparency of unit’s activity and results received. 
8. To monitor PPP according to indicators suggested and to provide the results to above- 
mentioned Public Commission for consideration and revision. 
9. To calculate, identify and ensure funding needed for policy implementation.  
For Public (Non-Governmental) organizations - both professional associations and 
representing patients’ interests 
10. To participate actively in pharmaceutical policy formulation and consideration. 
11. To be informed about the results of monitoring and evaluation and possible changes in 
policy. 
12. To create a strong advocacy coalition involving professional associations and consumer’s 
rights organizations, media and so forth, that would be able to defend interests of 
patients. 
For International Non-Governmental) organizations 
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